Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Welcome to BoneSupport's Capital Markets Day 2026. It has been around two and a half years since we last met in November 2023. So here we are today. A warm welcome. My name is Charlotte and I will be the moderator for today. And we have a full agenda with people from the management team. Bone Support's CEO and also clinicians are going to talk about the fantastic products of Bone Support. We have a large audience joining us here in the room and also via the web. So you can ask questions here in the room, or you can send them on the web and we will pose them to management and the clinicians. So without further ado, please welcome Björn. The floor is yours.
Thank you. Hello. Great to see you here. A warm welcome also from me to Bone Support's Capital Markets Day 2026. It's a privilege for me to kick off the first session, but before I do that, I just wanted to put today's Capital Markets Day into a bit of perspective and into a bit of context. Here you see the topics of previous Capital Markets Days. And what I would like you to take home after today is really these four points of focus that we will go through today. Number one, strategy update: Bone Support's strategy remains very strong. What we're doing is that in order to fully unlock the potential of CERAMENT and BONE SUPPORT, we want to become even more segment-specific in foot and ankle, trauma, arthroplasty, and spine. We will talk more about that. The second topic that I want you to take home is that we are making an upward adjustment of the market potential that we see in the US for foot and ankle, trauma, and arthroplasty. The third topic that I want you to take home is around clinical evidence. Clinical evidence has been a core part of our strategy ever since 2018. It continues to be. We are announcing that we are continuing to invest in evidence across all four platforms, most notably so in spine, where we plan to conduct a multi-center study to introduce and start selling antibiotic-eluting CERAMENT in spine. In the US. That study we estimate will cost around 80 million Swedish kronor over three years. That is in line with what we have communicated before. We are also announcing that we are going to invest in a study in arthroplasty. That is not to get any market approval. We already have market approval with arthroplasty, but we are investing in a study to further penetrate the arthroplasty market. That study is estimated to cost around 40 million Swedish kronor over three years. The final topic we will discuss is the spine market. What I hope you take home with you is that in spine, we see a clear unmet need for antibiotic-eluting CERAMENT in spine. We are going to show you what our research in this field indicates and why we think it is an attractive space to be in. And also our plan is not only to get regulatory approval, but also to start penetrating that market. Those are the four topics that I hope you will take home with you after today's session. So my part will cover four areas: strategy, the unmet needs, current standards of care, and then the moat, meaning what protects CERAMENT. And if we look at Bone Support, the company has really transformed over the last couple of years. In the last five years, revenue has grown almost sevenfold. Cash flow has gone from negative to actually generating more cash than we actually need. We have stayed focused. We have stayed small. That is in order for us to continue to run very fast. Qualitatively speaking, our evidence has gone from interesting to actually challenging the standard of care. Our brand has gone from having no brand awareness whatsoever to now being a serious market challenger. And if we look back five years ago, Cerament G was not approved for use in the US. So we had almost no penetration. Even today, when we look at the market, we have grown, but our penetration levels are still very low. So we are very early on our growth journey. And the strategy that we currently have and that we will continue to apply was really formulated in 2018. It is based on three pillars: innovation, which is the core of this unique technology that focuses on bone healing and infection management. The next pillar in our strategy has been evidence. If you have something innovative in orthopedics and you want it to get traction, you need the evidence not just to convert the surgeons who use it, but you have to convert the multidisciplinary teams that are around them as well as the payers. The third pillar is focused on commercial execution. Once you have innovation and once you have evidence for that innovation, it is very simple in orthopedics. The only thing that you have to do is be very, very disciplined and very, very systematic and commercially get that product into the hands of surgeons so that it reaches patients. Those three pillars have been the strategy for Bone Support since 2018. It will continue to be the strategy for us going forward. However, we are taking this strategy and making it more segment-specific in the four segments I mentioned earlier: foot and ankle, trauma, arthroplasty, and spine. Why is that important? Simply because they are different customers, different clinical settings, and have different needs. So in order for us to fully unlock the potential of CERAMENT, it's the same product, but we need to be more segment-specific and cater to the needs that the respective customers have in these four segments, because the needs are there. There's no doubt about it. And if we look at bone infections, they are among the most complex, costly, and consequential complications in orthopedics. And the incidence is increasing in foot and ankle. One in five diabetic foot infections progress to bone infection, which is a leading non-traumatic cause for amputation in trauma. More than 30% of fracture-related infections occur after open fracture fixation. The incidence is more than 30% of fracture-related infections after open fracture fixation. And in arthroplasty, periprosthetic joint infections carry a five-year mortality that rivals many cancers, not only for the patients but also for the health care systems. So I think since I joined, I read this quote from the late Richard Rothman, a very famous orthopedic surgeon in the US. And I think the way that he describes it in this one sentence actually describes the potential or the need for our products. Telling an orthopedic patient that they have an infection is like giving them a diagnosis of cancer. This quote is 25 years old. More than that, it was recently repeated at the latest international consensus meeting for bone infection in Istanbul. So, bone infection still is a massive clinical unmet need. Cerament has a role to play in dealing with that. And if we look at the three segments that we focus on now, foot and ankle, trauma, and arthroplasty, despite the fact that these segments are different. The patients are different, and the clinical settings are different. The failure pattern is the same. You have a bone defect, you have an infection, but there is no single solution that addresses it. Cerament is really the first one. And when you don't have a single solution, what happens is that you have multi-stage care and high recurrence of infection. So patients come back. Infections do not go away. And there are significant costs. We believe that some of that cost, a lot of that cost. Not all of it, but a lot of that cost can be avoided by using CERAMENT because it clearly addresses the unmet need. And if we want to look at the scale of this, how big is this? We will talk about the market adjustment that is on the micro level. What I'm painting here is the macro level. What is the nature of the patient pool that we are addressing? It is millions of patients. 38 million Americans have type 2 diabetes and trauma. 54 million Americans have osteoporosis or low bone mass. And that is not the only pool that pushes patients into trauma. And in arthroplasty, 2 million primary hips and knees on average are done every year. So it is very clear about this cascade. It is almost an inevitability that some of these patients, more and more, will end up with a bone infection. So what is it then that CERAMENT does? Here you have a very simplified picture of a femoral fracture. So it is a broken thigh bone. You can get a broken thigh bone, a femoral fracture, from a car accident. You can get it from a tumor. You can get it from many different things. But essentially, the surgeon meets this patient with a bone where they have to fill a void, and they are afraid of infection. So that rectangle to the left describes the starting point where you have filled that void with some white stuff with purple dots. The white stuff is Cerament BVF, the bone void filler. It is a mix of calcium sulfate and calcium phosphate hydroxyapatite, which is a subcategory of calcium phosphate. The purple dots represent the antibiotics. And what happens when you inject this into the bone? Two things start simultaneously. First, that white stuff helps the human's own bone to regrow and replace the BVF. So after 6 to 12 months, the body has resorbed the CERAMENT and transformed it into its own bone. The second thing that happens simultaneously is that in the first 30 days, you have these purple dots, which are the antibiotics that elute in a predictable, controllable way to kill bacteria. We will get more into the details of how that works, but that is essentially what Cerament does. It heals fractures as effectively as autograft, eliminating the need for bone transplants. Why is it so important with this local elution of antibiotics, or in the local application of antibiotics? Well, you see it in the picture to the left. When you use a targeted approach to treat and manage an infection, Cerament provides a local concentration of around 90mg/l. Compare that to the standard of care, which is systemic antibiotics. You get a concentration level in soft tissue that is 15 to 20 mg/L. So, there is a large difference. But bone is not soft tissue. It is even worse. It has much worse vascularization. So clearly, you are able to kill the bugs where you want to kill them. There is no problem with patient compliance when you have local antibiotics like CERAMENT. The patient cannot pull it out. Patients can decide not to take their antibiotic pills. When they receive it systemically. Systemically, you can receive treatment intravenously or you can take pills. There is no patient compliance risk. The surgeon knows that this will provide the patient with antibiotics. So, that is very important. And this picture here really shows, and I would say that you should start looking at the graph to the bottom right. This graph really shows that you have a controlled elution curve of antibiotics. So the x-axis is time. The y-axis is concentration. It is a logarithmic scale. And you can see that it's very predictable over time. That is one thing. But even more importantly, it stays above that red line, which is called the minimum inhibitory concentration level. You have to stay above that line for a long period of time to kill the bugs. It is easy to administer a high dose of local antibiotics in the short term, only for the levels to drop to zero. That is not what you want, because then some of these bacteria will actually learn to deal with these antibiotics and become resistant. So this is one crucial part of Cerament combined with the picture that you see up there, which is the bone resorption. So here you have a fracture. It's a picture of the knee. You want to repair that fracture. You use plates and screws. That is the standard. And then in this case, you also use Cerament in the middle picture. And in the picture to the right, you can see that it has actually been resorbed and replaced by bone. Human's own bone has been reformed. So why doesn't everyone use CERAMENT? Well, the current standard of care has been used for decades, and it's largely based on organic bone grafts and systemic antibiotics. There are many advantages associated with all of those options. So if you look at autograft or allograft, autograft is a human's own bone. So typically you cut up an area around the hip and you carve out bone from the iliac crest. It's great. It is a standard procedure. It's very biological. The body recognizes the bone similarly to allograft. But allograft is donated bone from other patients. So it biologically works really well. But there are limitations. Part of the limitations relates to autograft. There is only so much bone that you can take out if you have a significant injury to repair. Also, you get a scar. It is a separate surgery. It is an additional surgery. There is a risk of infection. So clearly, there are limitations with autograft or allograft. There are other limitations, as they are not as good as autograft. And also there is an inherent risk of disease spreading from one patient to the other. Clearly, Cerament addresses the limitations of both autografts and allografts. And if you look at systemic antibiotics, why is that a good option? Well, it's proven, and everyone uses it all the time. You can use a broad spectrum of whatever antibiotics you want, subject to the limitations you see on the slide. And as I mentioned earlier, you do not reach the therapeutic levels you desire. The treatments are long, lasting for six to 12 months. You have a toxicity risk. Patients who receive systemic antibiotics are not happy. Just the other week, I was in Denmark and walked around with the surgeons in the ward. And one of the main things that two patients said was that, no, I really don't want to continue on these systemic antibiotics. It is awful. It makes me feel really bad. So CERAMENT G and V really address that. It regenerates bone and it delivers local antibiotics in a predictable, controllable way. That is the current standard of care when it comes to autogenic bone graft. For decades, there have been many alternative synthetic bone grafts and I group them all together. And this is actually a table that I took. I copied it completely. I did not change anything. I put those boxes at the bottom. But this is a picture from the Oxford Bone Infection Conference with Matt Scarborough. He put this overview together. I think it's a brilliant overview that sort of indicates. So what does the playing field look like. So, you have calcium sulphate to the left, biphasic. That is the category where ceramic plates include calcium sulphate, and then you have Bioglass and PMMA. All of these solutions have existed on the market for decades. Calcium sulfate was actually clinically documented as early as the 1890s in Germany. It is a great product in many ways; however, it resorbs very fast. So to get that controlled antibiotic elution curve is very challenging for pure calcium sulfate. If we go to the other side of biphasic calcium phosphate, it's actually on the other extreme as it takes too long. It almost does not turn into bone or it is not resorbed. And the last large segment is, perhaps not entirely accurate, but PMMA stands for bone cement. It's typically used when you want to fix primary or implants to the body. The big difference with PMMA and the other categories is that it does not resorb. It is essentially Plexiglas that you put into the body. So if you want it out, you have to have a second surgery to pull it out. Also, in terms of the antibiotic elution, it is not as well documented and controlled as we believe Cerament is. So that is really the current standard of care in what we call a competitive landscape. But these technologies have existed for decades. It is nothing new. Now consider the biphasic material. And we introduced this product around 2000. So, we are in this category. But what is it that makes it unique? We've talked about what makes it unique, but what is it that makes it so difficult to copy and replicate what we've done with CERAMENT? And as with all difficult questions in life, there is not one simple answer. It is multifactorial. And the way that we look at this is that the CERAMENT moat consists of six distinct interlocking barriers. We have 30 core patents valid until 2034. We have the evidence with more than 350 clinical papers and abstracts published. I will go into more details about the secret formula, but essentially it is a proprietary, experience-driven formula that you cannot really figure out just by looking at the patents. It's the know-how that we've built up. I will go into more details soon. We have the regulatory barriers. We are the only FDA-approved antibiotic-eluting bone graft on the market. Reimbursement. I will also talk about the fact that it is not just about our IDN, GPO, and NTAP status. It's about how the DRGs are assigned. We received some really positive news a couple of weeks ago related to the CMS proposed ruling on that. And then the last barrier is our go-to-market in the US. It's a non-exclusive call point-based independent sales rep model that we started when we split from Zimmer Biomet in 2017 and 2018. I would argue that is one key part of the success that we've had and that we plan to continue to have. It makes it very easy for us to penetrate the market, move fast and focus on this unique technology. So, a bit of a deep dive into this. Mode three is the secret formula. And what we mean here is that this is stuff that you cannot really read in the patents. So it comes separately. And essentially, it is a combination of advanced material science, years of bone biology research, and manufacturing and production experience at scale. And I say at scale, because it is one thing to manufacture and produce this in small batches. A couple of times. But to do it at scale at the volumes that we have done. You don't want to know the production yields that BONESUPPORT had a couple of years ago. Most of the stuff that we produced just had to be scrapped. Scrapped. Now we don't have that issue anymore. And of course, it is the combination of all those things plus the clinical evidence, both from a theoretical point of view and a practical point of view. So this secret formula is part of the moat. And it's not so easy to copy. Another moat is the regulatory barriers. And I would argue that this barrier or moat is probably the least understood or least appreciated by the investor community. And essentially, it goes to the fact that, as I said earlier, Cerament G is the only FDA-approved antibiotic-eluting product in the market. If you look at the category of bone grafts and calcium, I think we didn't have the wording here, but it concerns synthetic bone void fillers and resorbable calcium salt bone void fillers. It has fallen into this category since 1996. There are around 400 to 500 product indication combinations approved. That means between 10 to 20 approvals every year in this category. Cerament BVF is in that category. New products are launched all the time. We created the category together with the FDA. Of course, that is called Resorbable Calcium Salt Bone Void Filler containing a single approved aminoglycoside. Antibacterial gentamicin is an aminoglycoside. We were the first one in that category in 2022. It has been open for everyone to use it as a predicate device for four years. No one has done that. No one has done that. Is that because the space that we are in with CERAMENT G is not very attractive and not commercially viable? We don't really think so. So by setting the standards, you see that in the box below we set the standard in terms of the clinical settings and special controls that all future products will need to live up to in order to enter the space. And it's not only what you see here on the slide, but there are a lot of different things that future products will need to live up to. I am sure they will. I'm not saying that it's impossible, but it is part of the barrier. I think this is my second-to-last slide, and it relates to the last part of the moat, which is around reimbursement. As I said, reimbursement is not only about TAP ID approvals and GPO approvals. Those are important. As part of running the business, you have to get them in order to grow. We have grown, so we have secured them, and we continue to work on them all the time. But this example relates to DRG assignments, and the CMS came recently with a fiscal year 2027 IPPS proposed rule. And if you simplify it, you can say that this proposed rule increases the payments to support the standard use of CERAMENT G in the US. It is a long document. It's a long document. I think it's 1,600 pages. Of course, not all relate to Cerament G, but there are quite a few pages that relate to G. But if we simplify it and do our calculations based on the data that is in this proposed ruling, we see that the payments are increasing. We interpret this for G DRG codes, meaning codes where G can be used will increase somewhere between $5,000 USD per procedure to $11,000. It's not just one simple list. It is not very easy to draw simple conclusions on what this means. But we took an example here and looked at fracture-related infections. You see three DRG codes: 492, 493, 494. They exist already. So there is nothing new in that. What is new is what we've marked in blue. That is top level. That is the most complicated. MCC stands for major complications and comorbidities. So that is the most complicated. And that category remains the same. But the proposal is that they change the wording or the title to include the insertion of antibiotic-eluting bone void filler. There is only one antibiotic-eluting bone void filler approved in the US market. So essentially, that DRG code can only be approved or used when the antibiotic-eluting bone void filler is used. What happens when there is not a lot of extra money, specifically from $26,700 to $27,700? Yes, it is an improvement. But the key thing here is that it's a proxy. Or instead of using the lower codes, whenever a bone void filler is used, they can code it fully with this 492 code. And in this specific set that relates to fracture-related infections, the average payment increase for the hospital would be $7,900. Now, of course, what you all are asking is, well, what does this mean for this quarter? Nothing this quarter because it does not have any impact this quarter. This is a proposed ruling. We expect the ruling to be announced firmly in the beginning of August and come into effect starting October. But how fast and how much will this impact us? We do not really know. What we know is that it is very positive, and what we focus more on now is preparing ourselves and our customers to take advantage of this. This clearly reduces one of the barriers that we have. So. Sorry, I ran over a bit, but we are okay. So that concludes my presentation. I have taken you through the strategy and the unmet needs on a macro level. I went through. Current standard of care and competition. And then, lastly, we went through the components that protect this segment. Now I am happy to hand over to Anna Lee, who will talk more in detail about what it means to take a more segment-based approach with CERAMENT. Thank you. Thank you.
So, good afternoon everyone. So today, I will cover three areas. I will go into more detail regarding how we apply this segment-specific strategy and value proposition. I will also take you through the market opportunity and how we have updated our market model since the last time that we met. And finally, I will also provide some more insight into the market research we have done in arthroplasty and spine. Need to be a little bit more firm there. Yes. So, the CERAMENT strategy is applied. And at the core of our strategy is a very straightforward and powerful idea. As Torbjörn talked about before, we have the same core technology, but we apply it in different types of segments. And as Torbjörn also said, Cerament combines two essential capabilities: bone healing and trying to control infection. As you can see in the picture here, we are demonstrating our approach. There you basically have the recipe for how we work. We start with the early adopters. We start to generate clinical evidence in the form of initial case series. We expand to clinical data and longer studies, driving adoption, further developing standardized techniques, which also helps with hospital protocols and, finally, guidelines. That is what we also aim for. Importantly, we are also expanding from surgical treatments into prevention. And we look for adjacent market segments to move into, most likely arthroplasty and spine. So if we look at the different values, basically it's the same value all over: heal bone, repair bone, and protect from infection. But there are some different surgeons to work with. And the basic problem is somewhat different. So when it comes to foot and ankle and diabetic foot, the most important thing is to save the limb. And it is to ensure that the patient can stay mobile and preserve the function of the body. That really helps to prevent amputation. Amputation is a true disaster for patients, as the survival rates are really poor. So within five years, there is a dire situation for patients with major amputations. We are also translating. If we can do that, we can translate the value into health economic value with fewer surgeries, lower complication rates, and in the end, reduce hospital stays, which also positively impacts costs. Looking at trauma, the most important thing there is to protect from fracture-related infections or reinfections. Which leads to this outcome. Sorry. Which helps. To foster recovery and shorter hospital stays as well. Trauma is a large under-penetrated market. I did not touch anything. I think so, yes. So, trauma is a large under-penetrated market. And you will see that also when we come to the market model in arthroplasty, which is the latest segment where we have really made a strong foothold. We see here a strong growth driver. Preventing prosthetic joint infection will really be a benefit. And we have the opportunity to do so. Also listen to Doctor Miller here, who will present the study later on. He will give you a much deeper insight into how it is for these patients. Last, but not least, is spine. Here we see a significant future growth opportunity. We have just dipped our toes into this segment. Right now, we are focusing on bone void filler. But at the same time, we are preparing for market expansion and to have Cerament be approved in that segment. And I will come back to the spine. As I said at the beginning of our presentation, standardizing procedures is super important for this. And here you see some examples of different types of surgical procedures and application techniques that have been developed by our surgeon community colleagues around the globe and which have also been published. That is what we aim for. And that really helps to expand into new segments and subsegments. I will now move into our market model. For those of you who attended the Capital Markets Day 2023, you will recognize this picture, and perhaps you recall meeting Haugen and Torbjörn at various other meetings; during the Capital Markets Day, the data was triangulated by multiple sources, including market reports, surgical society data, CMS codes, and primary research. Data. Coverage was relatively strong there for synthetic bone grafts and allografts. While the data we had on autograft was a bit less transparent and often excluded from available data sets. This is important, as discussed earlier. It covers all areas, both synthetic and organic, including both autograft and allograft. And therefore, we need to have the full picture. Since then, more comprehensive and higher-quality data has become available, enabling us to refine the underlying assumptions and improve the accuracy of our market segmentation and total addressable market. In this section, I will provide a brief update on the most significant revisions we have made. So when it comes to that. The biggest changes we have made involve revision arthroplasty, which is larger than we modeled earlier; our previous work underestimated procedure volumes, but new data shows the market is bigger, and it has also grown over the years since we were last here. Second, local. I will go back to that as well. At the same time, infection has emerged as a leading cause of arthroplasty revisions, which also helps bring up the numbers. So, basically, we go from around 70,000 cases in 2022. And now we estimate the market to be around 120,000. Second, local antibiotics are already widely used in clinical practice. This was also underestimated. So we have also made some updates which you will see. We have also sharpened our strategic focus. So in the previous picture you saw four segments. Now we focus mainly on three segments in extremities. So this slide shows our updated US market view for 2025, covering the three core segments: foot and ankle with diabetic foot, trauma, and revision arthroplasty. And the biggest update there is in revision arthroplasty. But all have been upgraded due to growth over the years to a total number of 460,000. We also include tumor, but we are not focusing on that area. The infection incidence before. We also try to differentiate between prevention and infected cases. Here, we now take a more overarching view on it. And the use of local antibiotics is quite high. You will also see in the market research that I will show that this is the case. This is what surgeons say. And spine. We have not done much in this area. We have upgraded the number a bit, and the total estimates are quite similar to the situation in 2023. But we will do more research on those moving forward. At the bottom, you see how we expect our market shares to be within the different segments. As you can see, although we think that we are very successful in the US market, we are still just scratching the surface. So in diabetic foot and foot and ankle is where we have the highest market share, while in trauma it is still very modest. And there we have a big opportunity for future growth as well as in revision arthroplasty and spine. We have, as I said before, just dipped our toe in. Thorburn was also talking about how this is the current serviceable market that we are addressing. But there are a lot of other factors that will continuously increase the market size. We have discussed the diabetic patients. They develop diabetic foot ulcers. This results in the bone also becoming infected, where Cerament acts as a good placeholder in surgical trauma. We see a growing number of people with osteoporosis, which will also eventually increase the volume in our trauma segment and primary arthroplasty. Osteoarthritis is also growing. It is also increasing the number of primary arthroplasty procedures. So that will also. It will generate a lot more revision arthroplasty in the future, which will also come and help increase the market size. So, market dynamics are there. We estimate the biggest growth of the market between now and 2030 to be in foot and ankle, diabetic foot, and in revision arthroplasty. While growth is still expected in trauma, the majority of the growth in foot and ankle will be driven by diabetic foot. And we hope to be able to prove that earlier intervention can help even more patients in the future, which will grow that segment quite drastically. And we believe that it can reach around 100,000 procedures per year. Today, it is around 40,000. We calculate that around 40,000 of the 80,000 is diabetic foot. So now I will go into a bit more of our segment deep dives. And we will start with arthroplasty, and we are continuously doing market research to stay alert and to stay informed about how the market situation looks. So, this is the latest study we did for arthroplasty. And here we were looking at revision arthroplasty and also a bit into the prevention of infections in primary arthroplasty procedures. How do they do this? What do the surgeons do? And I previously showed that there are around 120,000 revision arthroplasties made in the US each year where bone grafts are used. Our quantitative research shows that 96% of surgeons consider infection prevention challenging. Recent data from the structured registries from 2025 shows that the most common reason for revision of a primary arthroplasty is infection. The use of local antibiotics in septic revisions is very easy to understand. But what we saw also in this research is that the surgeons are already applying local antibiotics in revision surgery, 54% in hip and 60% in knee. PMMA and antibiotic powder were the most common application forms. And when presenting the technology we have, without even mentioning our brand name. When introduced to the name Cerament, 82% found the concept compelling. Very appealing. And this is a very high number for a product like that. So on the next slide, the top section is also from the same research. And that was for primary arthroplasties. And this survey showed that local antibiotics are used in 40% of the cases already. Which for the future leaves a possible segment for us as well. We believe that this is primarily in high-risk patients and reflects the growing burden of comorbidities such as diabetes and obesity. In the bottom section. It is from an earlier survey we conducted in Europe and the US. It was specifically looking into prosthetic joint infections. Here we saw that surgeons are very concerned about prosthetic joint infection. The use of local antibiotics is critically important. And the current administration is through either PMMA in spacers or beads, or as antibiotic powder, or also mixed with bone graft, synthetic or organic. One other thing that was also observed was that surgeons are concerned about micro-defects in bone. And that is something that can occur in routine surgeries, fractures, primaries, and revisions. And this also opens up a significant segment for Cerament with the possibility of its injectable form. So, not just for larger defects, but also for small defects. Yeah. The biggest challenges with prosthetic joint infections are recurrence of infection, bone loss, and implant biofilm. 93% of surgeons expressed that PJI is a challenging condition. And 84% of surgeons express a lack of available technology and techniques that would enable the transition to one-stage procedures, things that CERAMENT can meet. So, the arthroplasty segment and moving into spine in 2023. When we were here, we said that we were going to start looking into the spine as well. And what has happened since then? Yes, we have obtained clearance for use in interbody fusion. We have done preclinical studies specifically looking into application methods. We have done a lot of research and held talks with customers in the spine market to understand the unmet clinical needs. And we have also started a targeted launch, which is ongoing. And we have also initiated and established a plan for how to take antibiotic-eluting Cerament to the US market. So this is from the latest research we have done in spine. And this also illustrates how significant the need is for antibiotic-eluting CERAMENT. There is a huge unmet need in spine. Infection anywhere in the body is a problem. But it is extremely challenging. If you get an infection in the spine, you cannot simply remove the spine. You need it. Therefore, these surgeons are even more prone to use local antibiotics to prevent infection or to find a variety of different ways to avoid this complication. In our research, 86% of the surgeons are already using local antibiotics for prophylaxis in at least some patients, specifically if there are comorbidities. And 75% of surgeons use local antibiotics for surgical treatment if there is an infection. The most common way to do this is by dumping antibiotics. Although almost all of them believe that it is not an optimal way to do this. So even though they do it. 82% of the surgeons consider the approach suboptimal. When we talk about how surgeons are working, 78% expressed a need for that kind of product in this area. So it is a great opportunity for us. The same applies to arthroplasty. We see a really high unmet need. And we see really high numbers for wanting to have a product like CERAMENT. So this is my last slide, and it details what we are currently doing and have initiated regarding the spine market. We are starting with a lead focused indication for posterolateral fusion, which is sort of the biggest segment and the most intuitive, and also where local antibiotics are actually exceeding those numbers I showed you in this area. This is the segment that is really driving up those numbers. So they are even higher than the ones that I showed. The idea is to build foundational spine data across the full Cerament portfolio. We are starting pilot studies right now to guide model selection and study design. In the next phase, we will do pivotal studies that could be used for pre-submissions. And finally, also submissions to the FDA. The timing for that is around 2026 and 2027. We hope to be done with that. The clinical strategy has also started to take form. We plan to conduct two studies initially: one single-center case series of around 20 patients focusing on VWF, and then a multicenter study comparing antibiotic-eluting Cerament versus standard of care. The estimated cost there is expected to be around 80 to 90 million Swedish krona, as previously stated, with timing starting in 2027. Regulatory pathway strategy. We believe it will be a de novo pathway, likely due to the novel spine indication and the claims, and we expect that to be done no later than 2031. Overall, what we see is a large and growing market based on the market models that we saw. We have gone from 380,000 procedures to 460,000. We see that there is a need and a future where this serviceable market will continue to grow. In all of the segments that we have now decided to focus on and to build upon. And we believe that Cerament has and solves a real unmet need for both patients and surgeons, and we hope that we will help a lot of patients. Coming back to life, avoiding amputation, and staying healthy. And with that, I hand over to our Chief Medical Officer, Michael Dieffenbach.
Thank you for the kind introduction. I will continue with the clinical update. The clinical update will follow the already established market segments. I am sure that you are all very familiar with the market segmentation, but to me as an orthopedic surgeon, it was somewhat new how easily you can apply market segmentation to medical topics. And if we look at the definition, we just have to exchange users with patients. We share similar characteristics, and this would be specific diagnoses or specific diseases. So here are our four market segments as mentioned before. Foot and ankle, trauma, arthroplasty, and spine. I will go through all four segments, following basically the same structure. I want to start with a patient case. Then I will follow with publications since the last Capital Markets Day. And then we look into ongoing and future clinical studies. So let's look into the foot and ankle. This is a case of a male diabetic patient in the age group of 51 to 60 years. He has a diabetic foot. Osteomyelitis, or in short, as we say, DFO. And he has a deformity of the midfoot. Now, maybe you're not so familiar with the deformity, but basically what you see on the top is the normal anatomy of a foot, and the bones are kept in place by ligaments, tendons, and muscles, which are innervated by nerves. With the progression of the diabetic disease, all these structures are weakened. The ligaments are weakened. The tendons. The muscles are no longer innervated by the nerves. And then the whole architecture of the foot collapses, which you can see here on the right side, in the middle. For example, in this case of midfoot deformity, the talus—the bone in the middle—points downward and pushes out the surrounding bone structure. So now the arch that you usually have on your foot is reversed into a bump, which you can see on the clinical picture in the right corner. If the patient walks on this bump, the pressure naturally increases on the sole of the foot. It creates a pressure ulcer or diabetic foot ulcer, which leads to contamination, infection, and DFO. Now, in this case, a deformity correction was performed by doing a bone osteotomy and a wedge osteotomy. Basically, parts of the bones are cut out, the architecture is restored, and internal fixation is used, which you can see on the fluoroscopy. This structure here is the intramedullary nail locked with screws and plates. The debrided bone voids are filled with Cerament G and Cerament V. CERAMENT V is quite visible in black in the middle picture. But then we use a new software where we can mark the Cerament, and it is marked here in purple color. So it is easier in the follow-up to find the region of interest, which is here at six months: Cerament has started remodeling into bone. And here is the follow-up at nine months. The architecture of the foot is well in place, the hardware is not broken and has not moved, and Cerament has remodeled into bone, now marked in green. Cerament V has protected and promoted bone healing. This is the first publication I wanted to mention. It comes from the group of Professor Hans Gottlieb from the hospital in Copenhagen, Denmark. It is called CLOSE UP, a favorable protocol for limb-sparing surgery in DFO. And here are the highlights of the study. It's a one-stage procedure with local débridement or minor amputation. Cerament G and Cerament V and primary wound closure 92 patients. Then for systemic antibiotics, the C-VIVO protocol was followed. So this means a short duration of intravenous antibiotics, followed by a five-week duration of oral antibiotics. And if we look at the results, the failure rate was 13%, with only four patients who had major amputations. And please keep in mind the benchmark: the amputation rate from the literature is up to 24%. So the conclusion of this study was that a defined protocol with CERAMENT leads to favorable results. The second study I want to show you comes from a group from Manchester. The title is Adjuvant Local Antibiotic Therapy in the management of DFO. And here are the highlights of this study. It involved 105 patients. All had surgical treatment, but then the cohort was divided into two groups. One group received Cerament G or Cerament V, which is called the local antibiotic group, and the other group had the conventional treatment without local antibiotics. If we look at the results, the reinfection rate was almost 20% in the CERAMENT group versus almost 50% in the non-local antibiotic group. The major amputation rate was almost 2% in Cerament versus 12.3%. So, a huge, significant difference. And as I mentioned before, the benchmark is 24%. So now the conclusion is very similar to the conclusion before from the Hallux group; a defined protocol with CERAMENT leads to favorable results. But now in direct comparison to a group which did not receive local antibiotics. On the next slide, I want to show you an overview of ongoing and future studies. I have this slide for all four segments. So, I want to introduce it to you first. In the top, you can see the timeline in short-term, mid-term, and long-term, starting over 0 to 2 years, 2 to 5 years, and 5 to 10 years. So starting at 2026 and then heading up to 2036, we have the studies color-coded here. So this is the normal progression of a study. You start with a planning phase. Then comes the phase after the study protocol has been finalized. The agreement is signed, followed by enrollment, follow-up, and data analysis. Then a manuscript is written, submitted to a journal, and published. So here we have four studies in the foot and ankle segment. I have a slide for each of them. So, I will just give you the overview here, starting with Preserve. That is an ongoing DFO study on the forefoot in the Netherlands. Segment two is currently underway in Basildon in the UK. Again, DFO of the forefoot, but here with a short duration of systemic antibiotics. So they already applied the early findings from this study. This study in Madrid, Spain, focuses on a special surgical technique to introduce a new third technique. You could say this describes how to treat special anatomical locations of DFO in the forefoot in the planning phase. Not written in stone yet, but very far advanced in the planning is a randomized controlled trial of standard of care versus standard of care plus CERAMENT G in the US. So let's take a deeper dive. The first one is the Preserve study, a prospective case series. DFO in the forefoot on 53 patients. The technique was a debridement and bone void filling with Cerament G, and that was done in ten hospitals in the Netherlands. The first results were already presented at the Orthopaedic Bone Infection Congress at Oxford this year, and from a starting point, 107 patients were treated with conservative treatment. So systemic antibiotics and wound care for DFO. But 50% failed this initial conservative treatment. This is a really interesting finding on its own, because it shows that the current standard of care in DFO leads to a failure rate of half of the patients, who needed surgery and would have benefited from earlier intervention. These 53 patients were included in the trial, and after a follow-up of 20 weeks, there was a 15% revision surgery rate. If you remember from before, that is in line with the data showing 13% or the data showing 18% from Manchester. There were no major amputations, which is really great for the patients, of course, and the wound healing was around 70%. Here it is. That Cerament promotes bone healing; it protects bone healing, while ulcer healing is more dependent on the deformity reconstruction and on the wound care. The second one I mentioned is the study going on in Basildon in the UK. London area, 25 patients enrolled. They are now in the follow-up phase. And this is the study regarding the short duration of systemic antibiotics. And the six-month results are submitted for presentation at the European Bone and Joint Infection Society meeting this year in Porto. Meta-Math. This is the surgical technique. 20 patients were enrolled, and they are now in the follow-up phase. It is a quite established technique. It is called a resection. Arthroplasty. Where to correct the deformity. A part of this bone and the joint is resected. And then CERAMENT is used to fill the bone and to surround the bone. The idea of this study is to establish a new surgical technique which can be used exactly for this. Very common cases of diabetic foot infections occur on the metatarsal heads. Finally, the last slide on DFO. It is the planned randomized controlled trial. Here the planning is quite advanced, so I can share some more details with you. It is only DFO on the forefoot. Why always forefoot? Ninety percent of the osteomyelitis we find in diabetic patients is on the forefoot. So this is why our focus is on the forefoot. The study includes 100 patients, split into two groups of 50: standard of care versus standard of care plus Cerament G. The study will be conducted at the University of Texas at two sites: UT Southwestern and UT San Antonio. Follow-up will be 12 months. I said we are quite far with the planning. The study protocol has been finalized. We are in the phase of signing the agreements. So, fingers crossed. We hope we can enroll the first patients by the end of the year. This was foot and ankle. Now continuing to trauma, foot and ankle is our largest segment. So the other segments will be a bit shorter. But in trauma, I have included some slides for Solaria. So maybe about the same size as foot and ankle. Starting with the patient case. So, this is a patient between 30 and 40 years old. Fracture-related infection of the right tibia after a gunshot injury and fracture fixation with an intramedullary nail. The case was provided by a surgeon in South Africa. The nail was removed and the bone was debrided and filled with 10 cc, or 10 millilitres of Cerament G and systemic antibiotics were started, and you can see on the right hand in this bright white color. Now, where CERAMENT G was placed and again, color-coded down here. And if we follow up the patient now at eight months, Cerament remodels into bone, creates new bone, which we can see quite well here. So this is the area where Cerament was placed. And here you can see how nicely new bone is built, color-coded on the lower side. And then at the 13-month follow-up, there was full weight-bearing and the patient is doing well. If you are wondering what these little white dots are, this is shrapnel, which was left from the bullet. So that will stay with the patient. Looking at publications since the last capital market day, the first one comes from Dr. Sandilands from Florida. It's on intramedullary nailing with Cerament G and fracture-related infections and osteomyelitis. Here are the highlights of the study. It is a case series on seven patients with fracture-related infection, where the reamer-irrigation-aspiration system was used. So this is a tool where you can clean the inside of the bone, flush or irrigate it, and remove the debris so that nothing remains. And then Cerament is injected via the TUCAN, and when necessary, in case of instability, a new nail is introduced. The mean follow-up was 14 months. No recurrence of infection, no major complications, or amputations. And here is the benchmark. The recurrence rate usually is around 13% in the literature, and it is 13.3%. It was the same benchmark we used for the FDA approval for Cerament G. Now, regarding the conclusion of the study. And for the conclusion of the study, I just put these two images here. This is exact. They show how the Toucan is used to precisely inject Cerament at the place where it is needed at the fracture site or where the infection is. And we heard that seven patients is not a large number. It is a small case series. But this is exactly what the surgeons in the US are interested in. To see how Cerament G can be used in a minimally invasive technique here, and how it can be used. It is a successful report coming from one of their colleagues describing this technique. And of course, this is a perfect promotional material for our sales force in the US to show how to use Cerament. The next publication is quite similar. It is by the same author. Now it is on intramedullary nailing, but now for fracture-related infection prophylaxis. So this is now about open fractures and preventing infection after open fractures. It is the same setup, a case series on nine patients with severe open fractures using intramedullary nailing. Nailing with Cerament G through the TUCIN, with a mean follow-up of nine months. All fractures achieved healing and union, with no cases of fracture-related infection and no amputations. And the conclusion again on these slides is a practical guide on how to use Cerament. And with this instrument, the CERAMENT Delivery System, which you can see here. So the token is basically a cannula inside a cannula. And you inject through this and place exactly the Cerament inside the bone where the fracture is and a bit around. Then a nail is introduced to stabilize the fracture. Final publication on open fractures. So this is a publication you might be more used to with heavier evidence. On the science side, it comes from Professor Anand Pillai's group in Manchester. Local antibiotic prophylaxis. In these difficult-to-treat Type B open fractures with a ten-year follow-up. The highlights. It is a retrospective evaluation on 76 patients with Gustilo-Anderson grade III fractures, showing an infection rate of 5% with four cases of osteomyelitis after a follow-up of 88 months. So if you do the math, that is about a bit more than seven years. And the benchmark is here around 15%, so far below the benchmark of infection from the literature, and the conclusion is that Cerament G is a safe and effective option for local antibiotic delivery to prevent infection. This is the slide on the evidence pipeline. Now for trauma. You are now used to the setup. The Solario study. We talked about this previously, and it is close to publication. Then there is a combined study that is being conducted in Gothenburg, Sweden, where Cerament G and V are applied together in a bone void. The Certitude study in the UK. That is a post-market surveillance study going on at Oxford and the Conviction Trial, a randomized controlled trial in France. I will go through this in detail, starting with Solario. I took this picture at the 2024 meeting, where Professor Martin McNally is presenting the first results on SOLARIO. Just to remind you, SOLARIO stands for Short OR Long Antibiotic Regimes in Orthopedics. The design was a multicenter, randomized, non-inferiority trial for a wide set of orthopedic infections, including osteomyelitis, diabetic foot osteomyelitis, and prosthetic joint infections. It was done in 500 patients randomized into two similar-sized groups of 251 and 249 patients. The standard regimen, which means at least four weeks of systemic antibiotics, and 251 in the short regimen, which was a maximum of seven days of systemic antibiotics. Now to the treatment. All patients had debridement, and all patients in both groups had licensed antibiotic-eluting bone defect fillers and initial systemic antibiotic therapy after surgery, and at seven days. The patients were randomized; in half of the patients, the systemic antibiotics were stopped, and in the other half, they continued based on the suggestion or advice from the ID physician. And then the follow-up was 12 months. These are the topline results. The endpoint was met. The short regimen was equally effective in infection eradication as the standard of care. So if you spin it around, the short duration of systemic antibiotics was non-inferior to the long duration of antibiotics. If we look at the numbers, the shorter systemic usage was five days versus 37 days, an average reduction of 32 antibiotic days and a total reduction of more than 11,000 days. Just inside this trial. And the Solario team did a calculation. If you take the weight of a small antibiotic pill, you can see how much antibiotics were saved just in this trial, and it amounts to 15 kg. So now imagine taking a huge suitcase. 15 kilograms of antibiotic pills were saved just in this trial. And this has, of course, a huge impact for the patient because this short regimen reduces the adverse events. And this is shown here on the right-hand side. So you have the patient numbers on the Y-axis, and you have the adverse events. The dark blue represents the group with no adverse events. So 80% in the standard long group had no adverse events. And up to almost 150 in the short arm had no adverse events. And if we look into the adverse events, moderate adverse events were 70 in the standard group, and this was reduced to 35 in the short arm, and in the severe adverse events, the reduction was even more significant. Why is Solario so important for CERAMENT and for BONESUPPORT? This is explained on that slide. So, as mentioned before, all patients received local antibiotics and empiric systemic antibiotics. And 19 different products were used in this study. About 80% were resorbable like Cerament G and Cerament V, and 20% were non-resorbable. So that is the PMMA, the bone cement. 81% of the resorbable products were Cerament G or Cerament V, which means 64% of all the procedures. So Cerament, and so this study relies heavily on the results from Cerament G and Cerament V. In summary, on Solario, the advantages of using CERAMENT plus a short antibiotic regime. It promotes patient well-being by reducing the side effects and the adverse events. It reduces the antibiotic costs. That is clear by saving the systemic antibiotics. It reduces costs associated with adverse events. And that is quite important because the adverse events are a cost driver in this study. So this would be the readmission of patients, maybe even being admitted to the intensive care unit. And then the costs really go up for these adverse events. It improves patient adherence, as Björn already talked about. So the surgeon or the physician does not need to rely on the patient taking his medication. The medication is basically implanted by the surgeon. It improves antibiotic use because it is placed at the site of infection, at the right site, at the right time, in the right dose, and it decreases the risk of creating antimicrobial resistance. With this excursus on Solario, I come back to the other planned and ongoing studies in the trauma segment. This is the study where Cerament G and V are used together in the same bone void; on the right-hand side, in pink, you can see the size of the bone void where the products are placed. And then in the follow-up bone healing, the study has been finalized and the manuscript is submitted to a journal. The Conviction trial in France, which is run and organized by the centers in France. It is a randomized controlled superiority trial. The indication is chronic osteomyelitis. The aim is to enroll 200 patients. At the moment. 48 are enrolled, and there are two groups: debridement without dead space management versus debridement with Cerament G; eight sites are now enrolling, but the enrollment is, as you could see, far below the forecast. So the. The Cerament group will probably need to come together. They are driving this study to decide if all these 200 patients can be enrolled. The next study is CERED. This is a post-market surveillance study with a very long follow-up of three years, and this was demanded by the FDA as part of the de novo approval. It is a consecutive case series of fracture-related infections, with 121 patients planned and 20 enrolled. It is done at Oxford, so the Oxford Protocol is followed at the invention site. Basically, it is a long study, but we are happy to do it for the FDA with a three-year follow-up. The last patient is expected to be enrolled around the end of 2027, with the three-year follow-up clinical study report due in 2031. For these results, we have to wait a bit. This was trauma. Now coming to the third segment, arthroplasty. So this is a 54-year-old patient with a PJI or periprosthetic joint infection and an osteolysis of the right hip. If you have a close look at the radiographs on the right, you can see the prosthesis, the shaft, the neck, the head, and the cup. And you can see the radiolucent lines here and this bone defect. These are characteristics of a bone infection. Then the surgeon performs a joint aspiration to see if bacteria can be found. When bacteria are found, it is considered an infection, as in this case. And a one-stage exchange with CERAMENT was done. So this is how the surgeon is applying the CERAMENT G. He is augmenting the cup and the stem. And so by this the CERAMENT is transported or delivered into the bone voids around the cup and around the stem. And then by implanting the cup and the stem. Here are the follow-up radiographs of this patient with this one-stage exchange, illustrating only one surgery for this infected hip. One study I wanted to mention on arthroplasty is coming from Charité Berlin. Its first author is Doctor Miller, and Doctor Miller will present after the coffee break online. So I will leave the details of the publication to his presentation. Here are just the highlights. It is a prospective study on 20 patients with confirmed PJI, with a recurrence rate of 0% and no recurrence in the follow-up of 3.3 years. And the benchmark here for the infections is around 15%. But all the details of the study and of the surgical technique will be discussed with Doctor Miller after the coffee break. Then join Doctor Miller after the coffee break. An overview of the ongoing and planned studies. The overview. Sarah-Jane. A two-stage study in Germany with CERAMENT G is used in the first stage. Therapy 2.0 is a continuation of the study at Charité. It is currently in the planning phase and not written in stone. This CERAMENT in arthroplasty, a heavier lift, is a multicenter RCT. The details. This one is the CERAMENT study. It's a pilot study, a small pilot to gauge the differences in the results in a treatment in a two-stage hip exchange. So in the first stage, this hip here, you can. Interesting. I would suggest I am not going to touch this. I will just continue with my presentation. I wanted to show you because you are experts now with the radiographs; you can see here again these radiolucent lines which show that the hip prosthesis is loose and probably infected. Usually, in a two-stage procedure, the prosthesis is removed. And this PMMA spacer. A bone cement spacer is introduced. In this study, in the Cerament group, no spacer is used, but Cerament is injected into the acetabulum where the cup is placed and into the proximal femur. It is done at the University Hospital in Munich. I have some more slides on this. So the first stage is the removal of the prosthesis. The placement of Cerament, which can be seen as Cerament G and V here, is into the proximal femur and into the acetabulum. Here is the acetabulum look, and then, after six weeks, when the revision is done, CERAMENT is still in place. So the bone healing has already started. The massive antibiotic elution led to the eradication of the infection. And then the new hip is implanted. This is the continuation of the Hip study Therapy 2.0. It is a prospective study of the hip in 30 patients. There are two new things. One is that this one comes with two retrospective control groups. One is therapy on its own because this new one has a shorter duration of systemic antibiotics. So again, following the Solario results. And the second is a control group where no local antibiotics have been used. Final slide on arthroplasty. So this is the plan, again, not written in stone. International multicenter RCT PJA of the hip and the knee. We are probably aiming for around 300 patients. But that has to be confirmed in a statistical sample size estimation. It is a single-stage exchange. The idea is to have one group with CERAMENT G and a short duration of antibiotics systemically versus the standard of care, which is no local antibiotics and the long duration. This will be done at, or we think about 20 hospitals and we are in the planning phase with our advisory board and with international experts in the field. And the costs have been estimated, as Jelle said, with 40 million Swedish kronor. Finally, spine. My colleague has already talked about spine and the strategy here, so I just jumped right into the planning slide for the studies. A plan in yellow. The first one is a single case series on posterolateral fusion. It is for deformity correction. So this image is not a standard approach. Usually, you have just a tiny incision. This is to correct scoliosis. So to reconstruct the shape of the spine. Twenty patients are planned. The treatment is the combination of Cerament and bone void filler plus autograft and instrumented posterolateral fusion. It will be done in a single center in Canada. Why Canada? Because in Canada, all three CERAMENT products are approved to be used in the spine. And the second study is the Heavier Lift. The multicenter study. Posterolateral fusion in high-risk patients for infection. So this is to show the prevention of infection to reduce the risk of infection, around the same number of patients as in arthroplasty, with antibiotic-eluting Cerament plus autograft. Multicenter and again in Canada, estimated costs are around 80 million Swedish kronor. And with that slide, I hope I gave you a good overview of the market segments and the clinical update. And I would hand over to Charlotte to moderate the Q&A session. Thanks for your attention.
Perfect. Thank you very much, Michael. So please stay on stage. And Anneli, perhaps you want to come up as well. So we have microphones in the room. And could we get a microphone immediately, please, because Christopher here has a question. Christopher. It has come this way on the other side. Thank you. Yeah.
Okay, great.
A question on the market model. So the 430,000 procedures, do you think that you could penetrate all of that eventually with Cerament G and V? And also, I am looking at the figure 115,000 for ongoing infections. And then you have 190,000 for the use of antibiotics; is the difference there? Is it for prevention, just to make sure I understand it? Or should we add them on top of each other?
I'll start with the first one in terms of what's reachable for us. So if we look at those numbers, you saw the penetration levels depending on the segment. It's a couple of percentages on trauma and arthroplasty, and it's slightly higher on foot and ankle.
Could I just interrupt because that was my second question? When you talk about penetration, is that out of 430? Yes. Okay.
Yes. Yes. So when we talk about penetration, I prefer to use penetration. But you can argue market share. But penetration is defined by the number of procedures where we believe we can be used as a bone graft or with antibiotics. So that's one piece. And then we always count procedures. We do not count value. We always count procedures. And then of course, in some procedures, more CERAMENT is used and in some procedures, less CERAMENT is used. But we start with that procedure count because that's important for us. So what's reachable, I think in the US, and the reason why we say that we're still on the growth journey, is simply because if we look at the US where we are now, number one, it's only a few years since we actually launched CERAMENT. It's just a couple of years. It takes time in orthopedics, that's number one. Number two is that if we would achieve the same level of penetration in the US that we have achieved in certain regions and countries where we've been much longer, then we would get not 100% of that potential in the short term, but a long runway. We know that we have data points where we reach 60% to 70% of the penetration. And in some countries where we haven't been as successful, we've only reached 30% to 40%. So we definitely think that range is doable in the foreseeable future. Longer term, we expect this total addressable market to expand. We talked about the cascades of patients. So, we're not overly concerned that there is room for us to grow. We just focus on making sure that we get that penetration, day by day, quarter by quarter. And then let's say in 2 or 3 years, do I think that the market size will expand even more? Yes. But this is the data that we have today. And that is also what we see today. Everything else equal, we also focused on the so-called preceding segments. I think that is a very interesting dynamic for us to follow in the medium to long term. But exactly how that will play out, we do not really know. But it's of course a very strong tailwind for us, if that answers your question.
And then the difference between 190,000 and 115,000 is that penetration.
Well, the way that I would think about it is that, first of all, you have the total number of procedures where bone graft is used, and some of these bone grafts are used with antibiotics and some of them without, whether for prevention or not. Yes, you could draw that conclusion, but there are also other nuances that we should take into account. But I do not know if you have any more questions.
I think in principle you're right there.
But there could be ongoing infections where you're not using local antibiotics today?
Absolutely.
Yes. Absolutely.
Great. Thank you.
Stan, did you want to add something?
Yeah.
Hi. It is on the same topic. I'm just trying to understand the model. Previously, you talked about osteomyelitis in infected patients. Around 50,000 and some 90,000 in prevention. So how do we go from those numbers to these 115,000 and 190,000?
From my perspective, I prefer to talk about the segments as they are, meaning foot and ankle trauma and arthroplasty, and stick to the definitions in foot and ankle. You have the diabetic foot, osteomyelitis, and fractures. You have fracture-related infections and, in arthroplasty, periprosthetic joint infections, so using the term osteomyelitis is a bit confusing, and different data points interpret the term osteomyelitis differently. That is why we try to stick to that. That would be my starting point. And then Michael, I do not know if you can share why. Why is the use of these different terms varied across the different categories of osteomyelitis, fracture-related infections, and periprosthetic joint infections?
Well, I think we have, over the last probably ten years in orthopedics, become more focused. And we now have all these definitions for these specific infections, which we did not have before. So before, everything was thrown into one bucket, which is osteomyelitis; sometimes it was even called surgical site infections. And the numbers were a bit all over the place. Now there are much more specific publications emerging with definitions for these infections and treatment regimens. And this is another way which we follow with this market segmentation as well.
So I cannot answer directly on your number, but maybe only closer to the.
Number, a little bit more flavor. Also, because what we see is that these procedure segments are now coming in with more patients that we were not counting on being able to provide treatment for before. So we are seeing more and more use in diabetic foot. You can preserve more and more of the foot. We believe that the numbers have grown, and in the case of revision arthroplasty or prosthetic joint infection, we significantly underestimated the use of local antibiotics in combination with bone grafts. So that has also increased this number.
Okay. But the 190,000 is that the preventive use.
That is totally used. So that is both infection and prevention and also based very much on the market research that we have done that shows that there is a much higher use of local antibiotics already. Preventatively.
Thank you.
So Tobin, you started your presentation today also mentioning the costs of these studies and Michael reiterated them. Can you talk a bit about why you put so much more money in one of these segments and how you distribute it over the years?
I will talk more strategically about how we allocate the capital. And then Michael can provide the assumptions behind why one is costing more than the other? So, on spine, we want to achieve two things. We are doing the study. Regulatory approval and surgeon buy-in, or simply being able to use it. That is number two. In arthroplasty, we have all the regulatory approvals. We are not doing it for regulatory approvals. It's all about creating more science, more evidence to convert more surgeons, and increase penetration. That is really important. When we look at the total potential of these two segments, arthroplasty is much more here and now, closer to us, and involves less risk. It is just a matter of going out and getting it, so to speak, in spine. We are not there yet. So, new indications, new regulatory approvals. But both of the segments to us look very attractive, independently of how we view them. So that is why it is almost a no-brainer to make the investments at this stage. Now, the two studies that we are currently looking at are designed slightly differently. And that is also the cost. So Michael, feel free to share the thinking around the studies.
Yes. And thank you, Christian. And you mentioned some of the parts. So the spine study, as you mentioned, will be used for regulatory approval. This needs higher scrutiny. This has to be perfect to be used with the regulatory authorities in the US in spine. We are not as far along in the process compared to arthroplasty. We have an advisory board. We have a lot of surgeons who are interested in doing the study and who want to contribute to the spine study. It is a starting point. We have to go out and find the interested surgeons. And concerning the costs, the calculation is that in spine we need a CRO, a clinical research organization, which we have to rely on heavily to get the study done to all the standards for regulatory approval, whereas with arthroplasty, we rely on the key opinion leaders. It's not written in stone, but it could be driven by one of the key opinion leaders, meaning that we don't need the costs for a CRO. And the costs for a clinical research organization for these studies are significant. So, these are the two differences.
You are saying significant, but not as much as has been speculated in the market.
I mean, what is being speculated in the market is up to the market to answer. I mean, on spine, let's be honest, the number that we communicate today here on spine is exactly the same number that we've communicated all the time. And there is nothing new on that. For those of you who have been in meetings and been in presentations, when we get these questions, what we say now is exactly how we have answered them in the past. So, it is around 80 to 90 million. Now, if other people have better or other estimates on how much studies cost for Bone Support. And, you know, it is up to them to answer that.
Please. Where is the microphone? Yeah.
I have it already. So I have three questions. The first one is, I guess you implicitly share the volume split between the three focus segments in the US. So it implies a quite clear major representation in diabetic foot, of course. So, two questions there. So, in your opinion, is there any factor we should account for that suggests a lower market share in trauma and revisions long term, if you consider? And also, I think it would be helpful if you could share the volume split in Europe between these three segments where you have been before in certain markets.
Okay, good. First question. No. So I don't see that there is a different sort of threshold that we can reach in foot and ankle versus what we can reach in trauma versus arthroplasty. All of them look very attractive at this point. We don't see a ceiling. That one is not going to be drastically different than the other. They will be different, but we don't really know yet. Foot and ankle has been a fantastic segment for us. Trauma is fantastic for us, but it's early days. It takes time. Arthroplasty. Again, we are just scratching the surface. So all three of them are very important for us in absolute terms. It is easier for us to provide this level of granularity for the US simply because we have much more granular data. And that comes from the go-to-market model that we have in the US, which I said earlier, is a non-exclusive, call-point-based independent sales rep model. And that is call point based. What that means is that we get data for 80% of all the procedures done in the US. We know the individual surgeon, who they are, and what they are using it for? And so we have that level of granularity in the US; in Europe, we don't have the granularity. It is more anecdotal, and we can make estimates. So, it wouldn't be fair to give an exact number for us because we simply don't have it. But do I think it will look completely different to us than the US? No, that would be my estimate.
Good.
Those were two questions. What was the third one?
No, I think maybe there are four questions here.
Oh, okay.
The next one is how big a factor is the ability to plan the procedure when it comes to the surgeon's decision on whether to use it or not. I think maybe some words on the diabetic foot versus trauma, for example, would be helpful.
I think it's a great question that we can ask Doctor Matuszewski when he presents. So park that question and then you hear it right from the surgeon. I think from our perspective. The principles are the same. Number one, you have to have an innovative product. We do that. Number two, you have to have the evidence. That is that. That depends a bit on which procedure you are going after. Third, you have to do it surgeon by surgeon. So I have to convince surgeons one by one. You could argue. Are the trauma doctors easier or harder to get in front of versus the foot and ankle doctors? Some say yes, some say no. There is no difference for us. We don't draw any major conclusions on that. The principles are the same. You have to convert surgeons one by one with an innovative product and with the evidence. And so far, I think it is still too early to tell. And we don't have enough data to say that. Yes, one is absolutely more difficult than the other. We have enough demand on all three segments as it is today.
Good. And then in years post-2026, let's say ten years out in time, how much faster do you think the local antibiotics patient cohort will grow compared to the total procedures? And a question to that is also, do you think. Is Solario expected to help manage these patients better? And also, do you think Solario could have an impact on US behavior?
What do you think of Solario?
It's a very good question. Basically, the orthopedic community has been waiting for this study. It has been waiting for these results. And it has been waiting to reduce this long duration of antibiotics. So I think, if you can avoid these problems for the surgeons and for the patients by reducing the duration of local antibiotics, this is a driver towards the use of local antibiotics and Solario. So I think it has a high impact. The question is, since it's a European study, what about in the US? It will probably take some more time to make it public and to get the adoption. Because the US is quite known for the long duration of antibiotics, they will likely stick to their existing protocols first. But on the other hand, if you compare it to the OVIVA trial. The trial is where it was shown that oral antibiotic pills are as good as intravenous antibiotics. This was adopted quite fast in the US because they immediately saw the benefit and said, oh, then we do not need these six weeks of intravenous antibiotics. The special application cannulas and so on. So it could go both ways, but I think the US will be more conservative regarding the adoption of Solario. But what we see starting now, and I mentioned this a bit in the clinical studies, that there is a huge interest now to prove the Solario concept in the segments. So we hear a lot about diabetic foot. Can we do a study on a shorter duration, like it is done in Basildon now. So this topic is gaining traction and will help to gather even more evidence behind the large Solario trial.
Thank you very much.
And I think a key point, which I'm not really sure about and cannot really quantify, but I think it will have a significant impact. And this is actually something that has been evolving over the last year. The last, I would say, year has been referenced in relation to the Solario study. It's one of the key things that Professor McNally says when he presents this, is that this study gives more decision power. On the orthopedic surgeons. They don't have to rely as much on the infectious disease docs and the systemic antibiotic regimens. So it gives them more evidence, more decision power. And I think it's not only good for society and the patients as such. I think it is also going to benefit us. But exactly when or how, we don't really know.
How important is the full publication? Do you expect to get an extra boost from that or is this, I mean, it's already published the top line.
Yeah. So top-line results were published in 2020 and at every conference that I go to, or that we go to, Saliras is mentioned. It has been talked about and referenced. They talk about the results. And every time McNally and his team are out presenting, they are presenting the data. So from an orthopedic surgeon perspective, it's already getting traction. It is already being talked about. So that is one thing. However, in many hospitals and hospital systems, or actually the clinical area that we are in, it is not only a decision for the orthopedic surgeon; it is a multidisciplinary decision involving the infectious disease doctors. And what that means is that in several areas, in many cases, they say, well, you know, great study, love it. We're definitely going to go with this. But where is the publication? Last time when I was at NOBIS in the west coast of Sweden. This was exactly the sentiment, that this is great. I will use it, but I cannot start using it because I need the publication. Where is the publication? So, yeah, it will have impact. But exactly how, we don't really know. And we have really good reasons to believe that it will come soon. But it's out of our control.
So after following you for many years, a couple of years ago, you did this booster program to get sales up. Now it seems you are talking a lot about the clinical side today. But isn't there still a potential to do some type of booster programs? So, what is hampering would be the wrong word. But what is holding your growth back? Is it the clinical side, or do you have the money to do booster programs as well.
You know what you want. Son tells me all the time we're doing all of this boosting. You know, we need to reduce the amount we are boosting. We have been doing a lot of boosting recently. I mean, what has been announced has been announced. But if we look at 2024 and 2025, we've invested a lot in the hybrid markets in the US. We have invested heavily in the US in 2025. And also, since I joined, we have invested a lot in the back-office functions to support the organization to drive more sales. The good thing is that as we grow, we build a stronger base. A larger base. We are not shying away from investments commercially in the US as well as elsewhere. And actually, the good thing is that they pay off. If you look at the HAWK, we will talk about the investments in the hybrid markets after the break. It looks really good. We have continued to invest in the US over the last two years to boost production. We have doubled the capacity of the business. That is something that we have done over the last two years, which cannot really be seen on the balance sheet or the P&L. So we continue to do that. But the reason why we put so much emphasis on this is that there is a lot of exciting evidence around Serevent, and this is part of the strategy. We have an innovative product, but in order to get it into the hands of surgeons in a segment-specific way, we will continue to invest in evidence. So we don't really change the strategy. We just continue to do what we have done historically. And it is more of the same, really.
We have a question from the web: does G cover both gram-negative and gram-positive organisms? So how is the determination between when to use G and V made. Are there an increasing amount of procedures where G and V together would be appropriate?
These are very good questions. So G with gentamicin is a broad spectrum that covers gram-positive and gram-negative organisms. So this is basically the go-to product, I would say, because even if. So, this is especially for the one-stage procedure where you're not 100% sure which bacteria you're facing. You could use Cerament G and Cerament V. CeraVance is more focused on Gram-positive bacteria, not Gram-negative bacteria. And this is a good choice. If a patient, for example, is transferred where a surgery has already been done somewhere else. And they found gram-positive bacteria, maybe even resistant to gentamicin. Then this is a really good case to use CERAMENT V. So when you know that the bacteria are there and that they would react really well to vancomycin, but the go-to is CeraG and CeraV for the staphylococci, the gram-positives. And there is one part which is interesting for PJI, the periprosthetic joint infections here. The surgeons are performing this joint aspiration. So they find the bacteria even before they do surgery. And there are a lot of gram-positives. Vancomycin works really well against these bacteria. So I think there is a really good space for CERAMENT V in PJI.
I hope they are happy with that answer. So there's one thing that you have announced lately that we haven't covered at all. It is the buybacks. And there have also been some questions from the web. Why aren't you addressing this matter at all today. Perhaps Hakan will. But now we have you on stage.
Yeah. I am sure we will address it when he shows his favorite slides relating to cash flow. I mean, we are in a fortunate position. We are generating more cash than we actually need to do this. So we have plenty of cash. And also please bear in mind that the board proposed to the AGM to give approval for a buyback programme. The AGM gave that approval. Now, we didn't only do that for fun because we did it because we think it's adequate and relevant, but we will determine exactly when and how. We will announce that in the correct ways. But now the focus for us is to continue to operate the business the way that we want to invest in the business that we have done and that we show now that we want to continue to do. And I am sure Hawkins will soon give more information about how we start executing on the approvals that we have received now from the AGM.
In a while, before that, we are going to have some coffee, and please remember the A, B, or C that you received when you entered the room. So now there is coffee. But please, as soon as possible, go to your A, B, or C, and then we are going to rotate. So you get to see two of the product demonstrations before we are back here at 3:30.
And we have the eminent and great support of Karen, who is the director of medical education in Europe. She is responsible for the foot and ankle demo and for trauma. We have flown in. Candice Maxwell, who runs medical education in the US. And for arthroplasty, we have the eminent Pierre, who is the director of product management. So take the opportunity. You get to experience the products. It is really fun. You get to feel the product and ask a lot of questions. Thank you. There must be a spam filter, but it comes from you.
Adalimumab. Okay, okay, okay. However. I think.
But then you can.
Michael is going to be moderating this part, please.
Thank you. Charlotte. Welcome back from the coffee break. I hope you had some time for good conversations and some time to experience the products. We continue now with the clinical experience session, and it is an honor for me to introduce two surgeons who will present. Now we have first Doctor Sebastian Meller. Dr. Sebastian Meller is a consultant for orthopedic surgery. He is the head of the Department of Hip Arthroplasty and Infection Surgery at the Charité Universitätsmedizin, Berlin, Germany. And, of course, he will present on the arthroplasty market segment. He will deliver the first presentation online. And then after that, Doctor Paul Matuszewski will present. We brought him over from the US for this presentation in person. He is an associate professor of orthopedic surgery, chief of the Trauma Service, and chief of Trauma Research at the Department of Orthopedic Surgery and Sports Medicine, College of Medicine at the University of Kentucky. With that, he will present on trauma as the expert in that field. With that, let's continue and see if Doctor Sebastian Mellor is online. Sebastian, can you hear us?
Yes, I can hear you. Michael. Hello? Can you hear me as well?
Yes, we can hear you. Here in the room.
Perfect.
Now we can see you and your presentation. Wonderful. So thank you for spending the time with us. And we are now looking forward to your presentation on arthroplasty. The floor is yours.
Yes. Thank you. So once again, Michael, thanks again. Hello, everybody. And Guten Tag here from Berlin. It is an honor for me to talk here for the investor meeting. And I'm presenting our experience with SARA in our PJI cases. So let's start. PJI. Periprosthetic joint infections represent a challenging diagnosis. We face significant challenges. We have time-consuming surgeries. We have high costs, worse function, and worse outcomes. And we have high morbidity and mortality. For our patients, in some cases we have higher mortality rates than in some cancer cases. So that is really a big problem. What does PJI mean? PJI is an infection of a joint replacement and the surrounding soft tissue and bone tissue. It is biofilm-driven and it is mostly caused by bacterial pathogens. The diagnosis can be difficult. So this is why we need clear classification systems like the EBJIS or the Charité definition. PJI often requires revision surgery. Implant exchange and prolonged antibiotic treatment. This is why we have to talk about the PJI treatment in the future. Why are we performing hip revisions? These are the data from the German Arthroplasty Register. And you can see that almost 30% of all hip revisions are caused by infections. So we are talking about a high number of patients, a high number of cases which we are dealing with in hip and also knee revision. If we look at the revision rate. These are patients who are revised and then revised again after a hip revision. We see that in septic cases. And these are represented by the blue line. In septic cases, you have 30% revision rates after one year, which increase further over two or three years. Even in aseptic cases, this is the red line. You can see 10% up to 20% in 5 or 6 years. We are talking about suboptimal results in the real world. So this is why we have to improve our results. And we have to talk about strategies to improve these results. And this is why I would like to present our surgical treatment strategy for these patients. The goal is to take the less invasive approach with the best results. And you can see here this is the treatment algorithm for chronic PJI treatment. You have to remove the prosthesis. You can do it in a one-stage, a two-stage, or a three-stage exchange. Let's talk about the so-called one-stage exchange. For that, you need good patient selection. You need good soft tissue, good bone, and no systemic infections. These are the indications for a single-stage PJI treatment. From our point of view, the current gold standard worldwide and the most frequently used technique is the two-stage exchange. The two-stage procedure involves two separate surgeries. In the first surgery, you explant the prosthesis, and in the second surgery, mostly after 6 to 8 weeks, you perform the reimplantation and implant the new prosthesis. So this is called a two-stage surgery. And this is the most frequently used technique. In the meantime, the single-stage exchange is a reliable option which is becoming increasingly popular with growing application in centers, and the success is comparable between single-stage and two-stage PJI of the hip in selected patients. So in good hosts, with sensitive pathogens. This is a point which we have to consider if we talk about a single stage exchange. However, the failure rate in PGI treatment for both single-stage and two-stage procedures remains high. We have re-infection rates with strict criteria of more than 20%. It is really important to identify and modify risk factors which can be involved for better outcomes. That means host factors, local antibiotics, defect and dead space management. These are the three key points from our point of view. To modify and to improve results in PGI treatment. So let's talk about our surgical approach for a single stage exchange in these patients. And to proceed. To illustrate our procedure, I want to present a case. This is a typical case. A 59-year-old lady with PJI of the right hip. Hip arthroplasty was performed a few years ago. And you can also see on the right side a CT scan with some holes around the cup and with some defects. So from our point of view, this is a good patient for a single-stage exchange. So what we did was perform a puncture aspiration before the procedure. We found a pathogen, Staphylococcus capitis, in this case. So we decided to go for a single-stage PJI treatment in this lady; we used Cerament G with some allograft in the bone defects in the acetabulum. You see it here on the video in the middle, we fill the defects with cement and allografts, and then we go and implant the new prosthesis in this newly filled acetabulum. And then we are happy because we have local antibiotics. We have defect management for the new implant. So let's talk in detail about our augmentation technique using cement in these cases. So what we do usually in the first step. After removing the prosthesis, we absorb blood and fluid, and then we go deep into the femur and fill the hole. We channel retrogradely without pressure deep into the femur under the stem with Cerament G. You see it here? It's quite deep. After removing the compress, we fill the cavity retrogradely. This is step one and step two. The next step is an augmentation of the implant. You see it here. Every implant surface has some grooves, some notches, and some holes. And you can augment these implants with cement as we did in this case. Then you proceed according to your standard protocol and implant the prosthesis to this position as planned. You see here again the augmentation of the surface of the implant. 360 degrees on the implant surface. And then you go on with the implantation of the prosthesis. In the next step, it is step number five. We fill and augment the dead space. You see it here in between the prosthesis and the bone. There is always some dead space. There is always some defect. So we go and fill it up with cement to avoid dead space, to avoid hematoma. Because this could be the next position and the next space for bacterial infection. This is why we fill it up with cement. And in the next. In the next step. Step six. The next step. Step number six, we dry the bone bed. Do you see it here? Usually, I take a compress and push. Compress this cement for 8 to 10 minutes. Wait until it is fully set and hardened. And then you can see it is very nice. It should be fully set and hardened. And then we are happy and can go on with the surgery after the cement is dried. And in the last step, according to your protocol, make an X-ray, check the position of your implant and you can also check the position of the cement. You can see it here in the red marked areas, the cement in the proximal and also in the distal part of the prosthesis. This is our augmentation technique for the femur site. And surely we also have an acetabulum, and this is what I have here. The cement in the cup revision. And this is the same principle. We dry the bone. We absorb blood, use some compresses, and use a suction device because you need a good dry area for good visibility and application of the cement. In the second step, you go on with the application of the cement. It is applied into bony defects. You see it here. These osteolytic areas, these holes in the acetabulum, are filled up with cement as shown here. You can do it with or without allografts. If the defect is a little bit bigger. You can also take some allografts, as I will present in the next section. Again, apply some cement, layer for layer. And then after the cement, you take some allografts, you see here some chips, and then you can put it on the cement, make some compression, go on with a reverse reamer or with a pusher; you can compress it and fill up the holes and the defects very nicely. And you will get a nice osseointegration in this case, in the next step, it's step number three. It is again the augmentation on the implant. You see it here also on the surface of the implant, much like the femur revision you have in the acetabulum. Also, implants with notches, grooves, and holes. And you can fill them with cement. And then according to your standard protocol, you go on with the implantation of the prosthesis in the prepared acetabulum, like you do it routinely, and you can complete it as per standard protocol. So you put the cup inside and then, yes, now it's in situ. Take the right position and then fix it. Fix it with your hammer. Yep. Step number five. Also here, filling and augmenting of dead space and defects. You see it here in between the cup and the bone. There is also remaining dead space and some cavities. You can fill up and close these defects with cement. And also in the last step, step number six, you can compress and let the cement set for 8 to 10 minutes until it is fully set and hardened. In step number six, you perform the X-ray. And also in the X-ray, you can see the cement around the cup, in the holes, and in the cysts. And then this is also ready, and the patient has a new hip after a one-stage PJI treatment. So what are the pitfalls in using cement from my point of view. First of all, incorrect patient selection. So you need good, strict selection criteria for a single stage. This is necessary, and further pitfalls from my point of view are insufficient drying of the bone. It will result in poor adhesion. So dry the bone for the next step. The next point is high-pressure application. Do not use high pressure. Apply it slowly. Take your time. Otherwise, you will get maldistribution in the system. Number four, the incomplete filling of these defects or dead space. So residual spaces between the implant and the bone remained. So again, take your time. Fill up the holes, fill up the dead space. With a Cerament, make an X-ray, check if there are some holes, and you can fill them up with cement, and number five: don't close the wound too early. Wait until the product has hardened for up to ten minutes, and once hardened, you can proceed with a good soft tissue closure and then you will be happy. And also the patient will be happy. To verify the things I told you and to verify our protocol, we performed a prospective study which was published a few months ago. The cementless one-stage hip revision arthroplasty with cement in infected hips. So we called it a study. It was a pilot study. And I want to present you the design and the results of this study. It was the first prospective study using Cerament in PJI cases. And we included confirmed PJIs according to the criteria. And we involved 20 study patients in this prospective study with a follow-up of at least two years. And we used Cerament with gentamicin in defects and dead space around the stem and also around the cup, like I showed you before. So then we followed up the patients with a standardized protocol, as is typical in our unit. Regarding patient characteristics, we included 20 patients, ten men and ten women with PJI of the hip, with a mean age of 66 years, and 16 patients had cementless implants in the previous surgery. In the previous surgery, four patients had a cemented total hip arthroplasty. The stem was cemented in these cases. In these cases, six patients had one previous revision, but it was aseptic, so it was not a PJI case before. So, the intraoperative characteristics. We confirmed PJI in all patients. Intraoperatively, we had positive microbiological or histopathological results, and on average, we used 13.2 ml of Cerament per patient; postoperatively, 19 patients reached the follow-up. One patient had a lymphoma and was not able to follow up. We had one aseptic dislocation of the cup. We had no wound complications and we had no drainage. After the discharge of the patients, we found 60% of coagulase-negative staphylococci. A typical cohort, Staphylococcus epidermidis was the main pathogen, and polymicrobial infections were 20%, with culture-negative cases at 20%. So a typical microbiological finding in a PJI cohort. The results. The postoperative results for the score also improved significantly. Also, the EQ-5D-5L improved. That is the life quality score. So the patients felt better after the surgery and were happier. Also, the pain evaluation improved significantly in the SARP cohort. In this study, results were also significant. So very good results in this cohort. And we can say that after approximately three and a half to four years of follow-up. We had no reinfection. We had very good, excellent functional results and good radiographic results. Limitations include the need for longer follow-up and more patients for future investigations. But you can see it works. And our study could prove that it worked. That it works in our hands. Let me mention that we also use Cerament in two-stage exchange procedures. I have also brought one case for a two-stage exchange. That means this is a typical case for a two-stage procedure. You can see it here on the left side. The patient underwent several surgeries prior to the hip replacement of the left hip, including explantation, reimplantation, and fracture management. Also, there were some different pathogens. So the patient was referred to our unit. We did an explantation and a Girdlestone procedure. As you can see here on the right X-ray. You see, there is no implant inside. So, after six weeks, we performed a reimplantation in our unit. And we decided to use Cerament mixed with some allografts for the defects. There were some defects in the bone, around the acetabulum, and also around the femur. So this is why we use Cerament also in the two-stage in the reimplantation procedure. In this case, so far, the patient is doing well. And I wanted to mention that we also use cement for prophylactic use. That means we have patients who are at high risk, such as post-revision patients with comorbidities. And this was also the case in this lady. You see it here. She received a nail following a fracture of the left hip. And after a few years, she developed osteoarthritis. You see it on the left side. She suffered from pain and was not able to walk. Probably. So, we removed the implant. We removed the implant and in the same session we proceeded. We cut the neck, we removed the head, we cleaned the acetabulum, and we implanted a primary hip arthroplasty. It is shown here on the right side. Because she was very old, had previous surgery, and suffered from various comorbidities. We decided to protect the implant with local antibiotics to do it in a prophylactic way to save and to hope that the implant will be safe for the future. So we used it in single-stage and two-stage procedures. And also here, in prophylactic patients. So let's go to my take-home message. I would like to say that the two-stage is currently the gold standard. The two-stage is the gold standard, but the single-stage is getting more popular. We are becoming more confident worldwide. And so, more and more surgeons are performing single-stage PJI cases; for the single-stage revision procedure, we need critical patient selection. This is mandatory. I showed you our algorithm for these patients. CERAMENT G is in our department firmly established in the treatment protocol as a local antibiotic-eluting bone graft substitute for defect augmentation. In the PJI treatment, the CERAMENT G is utilized according to a standard protocol. So we do a débridement and bone preparation, and then we apply it in defects and around the hardware in the acetabulum, in the femur, and also around the knee. The hip study showed good functional and radiographic results, and we also could use it prophylactically in high-risk revision cases, like I showed you before. So this is my team. I always say thanks to my team and thank you for your attention.
Fantastic. Thank you. Thank you, Sebastian, for this great presentation. I'm not sure if you could see the audience, but what was really appreciated with the videos, I think, and I saw some smiles when you were hammering in the prosthesis. I think this is one of the highlights of each implantation procedure.
So all of you are invited to come to my surgery room if you want to see it live. No problem.
Sebastian, we have some time for questions. You can just hear my voice. So I will repeat the questions and I will ask the audience for questions, but please formulate them briefly so that I am able to repeat the question. So, no numbered questions like one, two, three, four. Okay, let's start with Christopher.
Would you say that Cerament is as beneficial in the two-stage procedure as the single-stage procedure, or is it mainly in single-stage that this is useful? Thank you.
Thank you. From my point of view, if the indication is there, you need local bone graft substitutes and local antibiotics with a high concentration. If you need a bone graft substitute for defect management and for dead space management. It is also a good idea to use it in a two-stage procedure. This study was about single-stage procedures, but we also use it now. In some cases, if the indication is right, in two-stage cases as well. Yes.
Great. Great answer. And it's fantastic. Of course, when you use the microphone, I do not have to repeat the question. That was a mistake on my side. So, Sebastian, the next question.
Yes. So, Doctor, in approximately what percentage of your overall procedures do you use it today? And where do you think that number should be five years from now or so?
Currently, we use Cerament G in all our single-stage hip procedures. Why? Because we had good results like I showed you in the study. So we have a good working system. So, never change a winning team. So this is why we use so many Cerament G in these single-stage exchanges. We will look into how our results will be in two-stage and also in prophylactic patients. But I can imagine that if it works and if the results remain good, we can go and use it there as maybe a standard product. If you have defects, you need a high concentration of local antibiotics.
Thank you. My second question would be, would it make sense to use it prophylactically in primary hip procedures?
So the question is if there is some space for the Cerament. Normally, there are no bone defects. There is not much dead space. So you don't use it. But some primary cases are difficult. In some primary cases, you have osteolysis. You have defects. And there it could make absolute sense. It makes sense to use it in these cases. Yes.
Thank you.
Yeah. That is a great answer. It really depends on whether there are bone voids, as you of course know, it is a bone void filler. So if there are bone defects to fill, then it makes sense. But sometimes there are no bone voids. So then the application is tricky. Great answers. I think we have time for one more question if there is interest. No further questions. So Sebastian, once again, thank you so much for presenting from Berlin all your experience from the Charité. Well done.
Thank you. Have a nice day. Bye. Good luck.
Thank you. And now, it is an honor for me to introduce Paul Matuszewski. Dr. Paul Matuszewski, a professor at the University of Kentucky, is presenting on trauma. I will step down and make space for you.
Thank you.
All right, it is a privilege to be here to talk to you today. And it is certainly good to share our perspective, having come all the way from the United States. My goal that I wanted to impart to you all today was essentially to give a little insight into how we use it and how it's been helpful for us, but also to understand really what the burden is. I think that you can talk about market share and things like that. But I think it is really important to understand from the patient's perspective and a worldwide perspective how big of a problem infection is for us. So the socioeconomic effect and treatment of fracture-related infection is quite high. Some of the prior speakers talked about this. The rate of infection has largely been unchanged and is anywhere between 1% to 30% in patients. And why is that? Well, it turns out that we're getting better at taking care of patients. So it used to be that patients would have traumas and they would die. But with advances in automobile safety and also some of our trauma care, we are able to keep these patients alive. So when these patients survive their injury, they become the broken, so to speak. And that's where I come into play. And so, as these patients survive more, we have a higher rate of complex injuries. And when you have complex injuries, you have a higher rate of infection. So when you look at it from a worldwide perspective, the burden is huge. So, each year there are about 178 million new fractures. And that corresponds to about 1.8 million fracture-related infections, which is quite a significant number of infections every year. Treatment for infection is expensive. It can be anywhere from up to six and a half times more expensive than the original cost of fracture care. An older study published suggested about $108,000 per case. But it is likely more. A lot of that cost comes from staying in the hospital. These patients get admitted with their problem, and they stay in the hospital for several days, often requiring multiple readmissions. And that is followed by the cost of the implants and the pharmaceuticals. And as these patients become more sick, older, and so on and so forth, that expense increases. So when you think about that worldwide, extrapolating those numbers. If you're spending about $100,000 US per infection and you have 1.8 million, you're talking about upwards of $200 billion a year spent on taking care of infection. And when you look at it as a society, that number is probably a little bit lower than what we really expect because the cost is tremendous. In the United States, there is about a 45% increased odds of requiring some type of governmental supplemental financial support, meaning patients who are on disability and receiving benefits from the government. But what about the actual individual? I just talked about the numbers for society. Well, the cost is tremendous and you have to think about it and look at it from the perspective of how good we are at treating infections. It turns out that for infections, we are about 60% to 70% successful for the early infections. When someone has a fracture, they undergo surgery. They wind up with an infection. We can treat them with a debridement, washing things out, retaining what they have, and administering antibiotics. And that is about a six-week timeline, give or take. But if you have a late infection where the infection is set more into bone, that's when we talk about removing implants and debridement, cleaning things up, giving antibiotics, and returning to the operating room, potentially for another stage not dissimilar to the PJI literature. Similar success rate, but now the timeline is increased. So now we're talking about three months. These timelines are only applicable if the treatment is successful on the first try. So that's historical data. So we've looked at this at my institution. And I have to say, as an egotistical surgeon, this was prior to my tenure. So I do not know how much better it is now. But only 43% of cases were successfully treated with two stages, 29% with three stages, and 27% with four or more stages. And that is with an overall success rate, including those stages, of about 60%, with 32% having recurrent infections, and with those recurrences happening between 8 and 9 months, with multiple complications. Patients receive amputations and suffer from complications associated with IV antibiotics, delayed wound healing, and similar issues. So, getting back to the patient, I love this picture. This is a perioperative care pathway from our preoperative unit at my hospital. It shows how straight a line everything is in a hospital. But we primarily talk about the diagnosis and eradication. But there is a lot going on during that time. I just told you that some of those timelines are six weeks, three months, six months, and nine months. A long time goes by. Think about yourself. If you were out of work for that amount of time, what would happen? What would happen? So, upon first diagnosis, patients are frustrated. It is like hearing they have cancer. We heard that earlier, but they are out of work. They cannot go to work. Maybe they have some benefits from the government. Maybe they do, maybe they don't. They have pain. They experience divorce during that time. They have problems in their family. They lose their job and they develop chronic pain and all sorts of things happen before the eradication. So the effect is tremendous on these patients. And they can be devastating. Patients have problems with immobility. They undergo amputations. They have complications from antibiotics. As we discussed. They lose function. They do not get back to where they were. Some of them go down the path of substance use disorder, where they become addicted to certain substances. And the emotional and mental impact is tremendous: anxiety, sleep disturbance, pain, concentration problems, depression, and even suicide are associated with this. So the long-term impact, though, is even worse. So once that eradication occurs, those problems still exist. They get past the infection and move on. They are not in the hospital anymore, but they have decreased quality of life. And the psychological burden persists even beyond four years. As that time increases, those themes worsen: the longer the treatment, the more complications and problems, resulting in a higher psychological burden. So where does that leave us? Well, the fractures are increasing and patients are becoming more complex. These complications and infections are increasing in prevalence but not necessarily incidence. So more and more patients are presenting, even though we are getting better at taking care of these patients. So how do we do better? What have we learned, at least in the trauma space? Well, we can actually take some of the data from the joint literature because they have shown in revisions that there are certain things that we can do; in the joint arthroplasty space, they have moved, at least in the United States, more towards outpatient procedures. So patients are no longer staying in the hospital for three or four days. They are staying maybe one day or even less than a day, and they are going home. And guess what? Patients do better. They have fewer complications, and they just overall feel better mentally. And then when we look at infection revisions. My colleague talked about this a little bit, but when you take a single versus a dual-stage procedure, it is a big difference for a patient. I just told you about all that time, right? So, you go to the office and you get diagnosed. And they said, okay, we are going to take out all of your implants, and then we are going to come back six weeks or three months later. Think about how you would feel while you are sitting there waiting to find out when you will undergo your next surgery. There is a lot of anxiety associated with that, and a lot of problems. So when you change that to a single stage, the mental impact is tremendous, and patients feel much better. So if we take that to the fracture-related infection side of things, we can easily, if we decrease the number of procedures, decrease hospitalization days and also the length of stay. Logically, we think that we would have the same effect. So can we do it? Well, I think we're working our way towards it. And I think that some of the evidence that was presented earlier helps frame this and provide context for us. And it all has to do with recent improvements that we're taking advantage of by combining those techniques. First, local antibiotics are a significant component in the treatment of infections. Historically, we administer IV antibiotics to patients. They receive it via IV. They go home with this every day. Someone delivers a bag of antibiotics to their house, and they have to administer it and sit there for 30 minutes. Well, the problem with IV antibiotics is that you can only have a small dose in your system, because if you get a higher dose, it could be fatal or lead to severe complications. So we can only administer a limited amount of antibiotics. Whereas if you flip the script and you give it locally, you can give orders of magnitude increased concentration. So instead of 10 units, you can give 10,000 units, so to speak, which is sort of like a battlefield approach to things. If you think of an overwhelming force in a war, if you hit everyone with everything that you have got, as opposed to a little bit at a time, you tend to be more successful. We look at some of the guerrilla warfare strategies that have been used in the past, and how it just takes a long time for these conflicts to go on and on. If you have an overwhelming force, things tend to de-escalate pretty quickly. So, what is the clinical evidence? There is actually a lot of evidence that is available. So you can use it in both prevention and treatment. Some of the prior speakers have talked about that. In the prevention space, there have been a couple of trials looking at vancomycin and tobramycin, which is another aminoglycoside not dissimilar to gentamicin, and they showed decreased infection rates when we used this in the initial treatment. So for treatment, and we've talked about this before, there are multiple studies that have shown that if you use local antibiotics, it benefits the patient. Okay. What about the decreased reliance on IV antibiotics? I talked about this a little bit. Well, IV antibiotics are problematic because there is a high cost of delivery. It is inconvenient and there are many complications. And one of the prior speakers talked about some of the findings of this trial, which I will touch on. But if you have an indwelling PICC line or an IV line in your arm for three months or six weeks, there is a high probability you will wind up with a bloodstream infection, which is a big problem for patients, and that can create all sorts of systemic issues and can even cause sepsis and death. So it's a really serious thing. And when you treat patients with IV antibiotics because of that, the guidelines are not clear. There is a lot of disagreement. Should it be for six weeks? Should it be for 12 weeks? So there is confusion surrounding that. So oral antibiotics are a very attractive alternative, right? Because it is easy to administer. It is a pill. It is lower cost. You avoid the complications associated with intravenous access. And actually, there is plenty of evidence now. So in the US there was the OVIVA trial which demonstrated that oral antibiotics are non-inferior to IV antibiotics in the treatment of fracture-related infection, and the OVIVA trial, which was mentioned earlier, shows a non-inferior result, meaning it is as good. Okay. What about single-stage treatment? Well, historically, I talked about the dual, the single, or the multi-stage treatment. But a more modern version of this capitalizes on this. Right. So if you use local antibiotics at the site of infection, outcomes can actually be better than if you do not use them. So now when we use those local antibiotics, we can take advantage of that in a single-stage scenario because we don't have to rely on systemic antibiotics as much. So the biggest thing is really a combination of all three. And with our powers combined. I chose this graphic here because this was popular when I was a child and I read it was popular in Europe too. I do not know if you recognize the cartoon Captain Planet, but it is all about combining forces to create Captain Planet. So the OVIVA trial is a lot like that. So you combine the local antibiotic therapy with the short course of antibiotics, and we showed that. They showed that it was non-inferior to a longer course, which we heard about, with a decreased rate of adverse events. So if we combine these improvements, it changes the landscape dramatically. Right. Local antibiotics, oral antibiotics, and single-stage therapy treatments change that paradigm completely and play a tremendous role in this. Because in the United States, that is the only thing that is available and approved to be a bone void filler that is combined with antibiotics. So that means that you get the local antibiotic delivery to help improve the eradication of infection, and then you get the bone graft substitute to fill the hole. Right. So that is the single-stage part. Previously, we would have to go in, take everything out, leave a large void, place something temporary, and then return later. Once the infection is eradicated, we put something back in. So it allows us to do both at the same time. Here is a clinical example for you that I think can be illustrative to kind of make these points. This was a 41-year-old lady who came to my clinic; she is a very active lady. She had a prior trauma. She was treated by another surgeon for her ankle fracture. She was a long time out from her original surgery, and she started to develop an infection in her leg. And this is what her X-rays look like. If you look at her X-rays, you can see screws at the bottom of her ankle. And if you look really high up there, there is something in there that is actually a drill bit from the surgery, which happens. It does happen. To remove that drill bit during surgery is quite difficult. There is a significant morbidity associated with that. So a lot of times we leave that in there. And if you look really closely, you can see at the tip of that drill bit, there is a little bit of fuzzy material there. And what that fuzzy stuff represents is some type of reaction to something, most likely an infection. So with this patient, I have two choices, right? So the traditional treatment is I could bring the patient into the operating room. Admit them to the hospital. Perform the surgery. Take everything out, give the antibiotics, send them home, and then bring them back after we have confirmed that the infection has gone. For a potential second procedure where we might perform a bone graft. Because I just told you that in order to get that drill bit out, I have to make a hole in the bone. So I have to create a hole. So how do I fill that? Well, I have to go back and bone graft that, or hope that it's small enough that it doesn't matter, or maybe take advantage of some of these techniques and use more of a modern strategy where I can do everything in one shot. So bring the patient to the operating room, take it out, and go ahead and put the local antibiotics with the serum and gentamicin in it to fill the bone. At the same time, discharge them with oral antibiotics, maybe IV antibiotics, and then follow them as an outpatient. And let's see what happens. So I chose number two because that was going to be better for this patient. This patient is a mother of three. She has to go home. She has to take care of her children. She cannot be in the hospital. There is no one else there to take care of her kids. So we performed her outpatient surgery on day one. We did what we said we were going to do. We removed the foreign body. We put our biphasic calcium sulfate hydroxyapatite, serum, and G. And then we took cultures and we discharged her home on the same day. We gave her two weeks. We gave her two weeks of oral antibiotics. She turned out to have an infection, her cultures were positive, and we referred her to infectious disease for a follow-up. Now, mind you, if this were the traditional way, those positive cultures that I just talked about on post-op day three, the patient still would have been in the hospital waiting for those things to percolate, and then they would get their IV line, which would take another day, and then they could be discharged home. And then all of the complications associated with that. So she actually wound up not getting any systemic antibiotics because she had complete resolution. So she did not need any further treatment. So this is definitely a success. Minimal disruption to the patient's life. She is back to work quickly. No additional visits or procedures. And how does the hospital look at this? And is there any evidence for improvement? Well, we actually did look at this a while ago, where we looked at the healthcare economics of this. And it all has to do with time. So the more time you spend away from work and the more time that you have to spend on procedures, the worse it gets. So when you change to a single-stage procedure, you have tremendous savings. This is probably a lower estimate of about $30,000 or so, with a large part of that being the surgery. And there is also an improvement in life years and quality-adjusted life years as well. So the bottom line is it's good for the patients and it's good for the payer, the health care system. We talked about that. But what about the hospital? Well, actually, the hospital side is a little bit more complicated. In the US, if you have a complication, the hospital still gets paid for it. So more procedures, more complications, more revenue. Right. Because things are not really tied to performance. Now that might be evolving over time, but currently that is how it is, at least in the infection management space. So the hospitals look at these things more on a per-case basis. At least they did at my hospital. And what we found is that when you look at the cost of care associated with infections, it is usually a loss for hospitals. They don't want to treat infections. That's why a lot of the centers in the United States, specifically the academic centers that take care of these complicated patients, receive referrals from other outside hospitals to manage their care. Why? Because the government supplements their overall revenue cycle to keep them alive. So that is how it functions in the United States. So when we looked at our cases, specifically Cerament G shortly after it was brought onto the market and I got approval at my hospital. They said, "Oh, you are losing money." You're losing about $4,000 a case from these patients. And I said, "Well, wait a second." What if we flip this on its side? And so when we flipped it on its side and we took this from an outpatient perspective, all those things I talked about, it turns out that we actually were making a profit. Well, the healthcare administrators love that. So my health care administrators are split. We have some doctors and then we have some folks who are more focused on the finance. The doctors say this is good for patients, so you should be doing it. But then the administrators are on the other side and say, we like that. But if you could do it as an outpatient, that would be better. Which, it turns out, is better for patients anyway. So it is not just the money, though. It is about our ability to take care of these patients more creatively than we were able to before, because not every patient is the same. Not every patient can be away from work, and every patient is a little bit different. I talked about that mother and how she was a little bit challenging to treat because she could not get away from home. But there are other things that are involved with this. Patients tend to avoid traditional care. They are afraid to go to the doctor because they do not want to deal with what is going on, which leads to even more problems. So consider this case. So I had a 48-year-old female. She had a bicondylar plateau fracture. That is a very traumatic injury to the knee. And she had an implant infection. She received treatment for the infection. She had the implants removed. And guess what? It was not successful. She came back to see me. About six months after the antibiotics were stopped, she had a recurrence of her infection and she had drainage. So she had a hole in her leg. And she is draining here. And this is a picture of her X-rays on the right, where you can see a hole that is clearly present. And then on the left, that is an MRI scan, which shows a white spot. The white spot represents fluid. And in this case, that represents infection. She has an infection in the middle of the bone. But this patient is a sick patient. She is not healthy. She is someone who has multiple medical comorbidities. And the last time that she had IV antibiotics as an outpatient, it was poorly tolerated. She experienced severe nausea, diarrhea, and kidney damage. So, the IV antibiotics caused damage to her kidneys. So she had a really rough course. So she said, I am not doing that again. She didn't want to be stuck in the hospital for three months or six weeks, because she wound up being hospitalized for a while for that, and she wasn't interested in following up with our infectious disease colleagues. She didn't like them, but she liked me. So, what do I do? Do I refuse her the surgery and say, if you don't do it my way, it's the highway. Or do we take more of an authoritative strategy and say, no, you have to have this, but will that patient comply or will there be an issue? So with these new techniques, ideas, and concepts that are evolving, we can take advantage of these findings. And I can offer her outpatient surgery with local antibiotics, debridement, and oral antibiotics. She was okay with that. So this is her post-op. This is her intraoperative photo, which shows the Surgi-G that has been placed in the area of that hole that I showed earlier. And she had complete resolution of her symptoms. She did great. This is two months post-op, and you can see that the wound is getting smaller and smaller by five months. So this was a success story, and she was very happy and able to move on with her life; this is a 49-year-old female patient with schizophrenia. Okay. This is someone who is in and out of the hospital, disappears, and does not come back. You see them one year and they might disappear for two, or they might have all sorts of issues. Compliance is an issue. They cannot go to the hospital. They cannot make their appointments. This is a standard problem that I see almost every single day. Okay. She had a prior trauma. She had external pin sites on her arm from an external fixator, and she had a draining wound. She has had this draining wound for years. If you look at the X-rays and MRIs, you can see in the red circles where it almost looks like something has exploded out of the bone. This represents the infection. And you can see it confirmed on MRI. There is that white spot that I was talking about before. So a chronic, localized infection and a difficult social situation. So, what do we do? We do exactly what I talked about. Local treatment, minimally invasive, oral antibiotics, and referral for outpatient antibiotics. So that's what we did. So here we are. This is a good example. I am very proud of this picture. Someone took this with a phone and it looks like it was part of a surgical brochure. So this is a small incision right here. And there is a cannula, which you might have seen in the presentations in the hallway there, with me injecting the local antibiotic. So, the incision is right here. And what that looks like on the X-ray is just that. So that is the humerus. That is the top part of the bone. And her infection is on the lower part of the bone. So that wire is introduced. We use that wire to guide us in creating a hole in the bone to enter the intramedullary canal. And then we use cannulas to get all the way down to the site of the problem. So that is a chisel that is used to get down to the site of the problem. And then once we clean that out and wash it out and curette that, that is the cannula on X-ray. And you can see there's a wire over here which is directing me where to go. And I slide that down into the bone. And then at this point, this is where I am with it. And then we put the antibiotics in its path. So this area here, where you can see, is actually hard to see on the projection. But if you look very closely, there is a shadow. And that shadow represents the radiolucency. So I am able to do that from all the way up here for something that is all the way down here to avoid opening the arm. Historically, what we would do is open the whole arm using a huge surgical approach. And I can do that through a pretty limited incision. So that's a big benefit for patients. The patient grew out MRSA, which is a tough bacterium. They were discharged on the same day, and they followed up one to two weeks later. Infectious disease prescribed an antibiotic that has to be a pretty expensive antibiotic. And guess what? She never received it. That is not ideal, but it is quite common, especially in my practice. But the local antibiotics are effective. I can take a deep breath because the patient is still getting treatment and they are still being 100% compliant. I don't have to worry about it. If she disappears. That is okay. She is taken care of. So here she is at six months. Mind you, I don't have any X-rays before that because that's when she came back, six months later. Normally, we see patients at two weeks, six weeks, three months, and six months. She came back at six months. Her stitches were removed somewhere else. Someone else took them out. I do not know who, but she did. Great. So. Conclusion. The number of infections is increasing, and the complications in these scenarios and for the patients continue to rise. And the patients deserve better. We are not that good. I just told you that when it works, it works 60% of the time. But guess what? It does not always work on the first try. So outpatient pathways can help us do that. And single-stage procedures really improve the quality of care and the cost of care. Thank you.
Great.
Wonderful. It is really impressive to see these tough cases and all the complications we sometimes do not think about, or how difficult it is to deal with the patient, not just to treat them. Are there questions from the audience? Yes. The microphone is coming.
Thank you for that. Very good presentation. I have a question. If you could talk a little bit about the process of deciding the risk of a patient potentially developing an infection. How clear is this typically to you after this assessment?
So, the question is, how do I decide if someone is high risk? Well, part of that is already set in stone for the patient. So some of these injuries have a pretty high risk of infection. So when you look at open fractures, for instance, the infection risk is quite high. If you look at the risk of what we call periarticular injuries, meaning injuries around the joints, such as the knee joint, the ankle joint, and the foot joints. The risk is anywhere between 12% and 25%. So these patients are very high risk. And those were the targets of some of those trials that I spoke about earlier to try and help prevent. So we try to identify these patients. But what's interesting about that is that when you look at that risk, we look at the high-risk injuries, but the question becomes, who really stands to gain? Is it the high-risk patients or the low-risk patients? Because the patients at high risk might actually wind up getting infections anyway for other reasons. Whereas even for patients that are low risk, if you have a 1% infection risk and you can reduce that to half a percent, that is a tremendous improvement because the number of those patients is much greater than the higher risk patients. So I guess to reframe that, I think it doesn't really matter, because both groups of patients benefit from some type of preventative treatment.
Good. And then I had a question before, which I will try again now with you here. So I imagine you are in a very stressful environment at work. So when it comes to the factors, the ability for you to plan procedures is not typically there when it involves acute procedures. So, do you typically get that question? So is that a decisive factor for the uptake of the technology compared to procedures that are easily planned weeks in advance?
Well, we see both versions of that in the acute setting and also in the reconstructive setting. So my practice is taking care of acute trauma, but I also have a little bit of a niche where I take care of some of these patients who have had surgeries and infections treated many times over. So to your point, does it help having the time to plan? Absolutely. But I think that this is something that's on the shelf for us that we can grab whenever we need it. And sometimes these patients come in early in the morning, and we have to make a decision minutes later. In my institution, each of us has a day that we are responsible for. So whatever comes in the night before, we don't know what it is. It is going to be a surprise. And that's what we have to take care of. So we don't have a lot of time to think about that. But certainly, this is a great tool to use. And we do use it on the fly. We don't get approval and then wait. We have to treat them right away. And it's perfectly used just the same.
Thank you. And then if a patient treated with this returns with an infection, what would you believe had gone wrong?
Well, nothing is perfect. And these patients are complicated, and it depends on the clinical scenario. And sometimes it can happen. Sometimes it can be as a result of an error on the surgeon's behalf or an inadequate debridement. We try to take responsibility ourselves, but sometimes these cases are more complicated. I had a patient that we had treated for an infection and had used Cerament G, and although it failed, they were better off this time around than the last time. So the first time I used Cerament G as part of a larger, much bigger procedure where they had extraction of implants and all sorts of things done, including an antibiotic-coated implant, and the Cerament G was used to augment things. The patient came back with a small area of concern for infection. Now, the big infection had been taken care of. So I just took care of this patient right before I came here, actually. And so we are able to go in and target it. That is one of the nice things about it; you can take a bigger problem, make it less complex, and turn it into a small problem. We can address that and still use it again.
Thank you so much.
Thank you. Great. Great questions. Here is a question from Christopher. We just need the microphone. But yes, please pass it on. That is great. It saves time.
Thanks. Considering your discussion here about the cost benefit with the product, I don't know if you were here earlier when there was discussion about the new reimbursement proposal from CMS and that Cerament G use would automatically trigger a higher reimbursement; is that something you see would drive the use of Cerament G in any way? Thanks.
Absolutely. I think one of the barriers, and I think the others touched on this too, as Cerament G entered the United States is the cost. So anytime that we add something that is new. This is a significant cost associated with it, and it is not cheap. So, I just told you that about that one. And when we looked at our value, we had a small negative margin. When you talk about fracture care, that is infection care. That's 50,000 to 100,000. So, we lost 4,000. Well, those are the kind of margins that we're dealing with. And these conversations do occur. The bottom line is that it's a huge burden because the hospitals are looking at it and they say, well, does it work? And they say, we are not going to spend the extra money to get it in. So when you add something like that for the DRG and support that, that's a big benefit. Because now in those cases, even in the inpatient cases where you see the reimbursement go up just a little bit, that's enough actually to turn that margin positive for the hospital. So when the hospital looks at it, they say, okay, I know it's better for the patients and it's actually allowing us to make money. So that's a big thing for hospitals. And that was a big burden for me. You know, that slide that I shared with you was an analysis after we got the technology approved. And when I went to my board to get approval, I said, okay. They said, "How many times are you going to use this?" And I said, I don't know, maybe 6 or 10. And about six months later, they said, okay, well, you used it about 40 times. That is a lot different than what you expected to use it. Well, there are other people using it too. And I said, well, that just happens to be the way it is. So they looked at the cost and they said, "Wow, this is costing a lot." And so, that board consists of administrators and doctors, and the doctors say, hey, this still works and this works well. So we're going to give you approval, but you need to be judicious about using it. Well, the administrators say yes, but why don't you use it as an outpatient, preferably to try and make that work for you. And that was a big thing. And this only adds to it. And at the time when I first started doing it, there was—and you have to correct me on the terminology—a new process. There was a new technology code where the hospitals received extra reimbursement for the first 18 or 12 months.
It was called NTAP.
And when they said, oh, wait, that is something that exists. And I said, yes. And they look back and they say, yes, we actually did get that. And then those numbers were even more positive. So these things are huge because hospitals are going to be very resistant to approving something like CERAM. And really, without that and now that you have that, that is a big deal. It's wonderful. It opens up the door because surgeons are waiting for it. And that is a common conversation that we have when I teach other people how to use this at all these conferences and they say, well, I have to get approval. This is how you get it. And then it just opens up the usage.
Thank you.
That was a great answer and great to hear the feedback from the administrators. And you already mentioned the feedback from colleagues, surgeons, and physicians. Did you hear any reactions there on your single-stage approach with Serom? And what are they saying?
Well, I think that one of the things in the conversations and the questions that are coming up that I think that everybody is forgetting to talk about is that physicians are very stubborn, especially surgeons. So getting change is tough. The things that I am talking about, my colleagues, some of the elders that have more gray hair than me, they are very resistant to change. And it takes a long time. It's like trying to move an aircraft carrier. It does not move very quickly. So the same thing goes for the infectious disease colleagues. They will see one study and they will say, oh, I saw that, but I do not believe it. Or maybe, but it is hard to go against dogma that has been around for decades. When you look at the standard of treatment with six weeks of IV antibiotics followed by a consolidation phase of oral antibiotics, that's something that has been established over the course of many years. And to go beyond that takes a little bit of a gestalt of confidence to do that. I think that some of those slides that I shared about those studies provide me with the confidence to do it responsibly. And when I first started doing this in my practice, I used this in conjunction with the most difficult patients because they had no other choice. So I said, we have to take advantage of what we know and how can we do this. So I'm going to use it for the difficult patients. Otherwise, they are not going to get anything. And when you look at that, then the infectious disease colleagues say, okay, and I force their hand. So I do not even tell them about the patient. Now I take care of them in the operating room, and then they follow up with them a couple of weeks later, as opposed to before they'd be admitted to the hospital. And now they have complete control over what happens in terms of getting antibiotics and staging it. So I set the stage now for these patients.
Great answer. Thank you so much for answering the questions. Thank you for your great presentation. And I ask now Håkan, Håkan Johansson, our CFO, to the stage for his presentation. And I think it contains the final conclusions, right?
Well, that I will do also together with Torbjörn later on.
Exactly.
So, thank you. And it feels like a bit of a challenge after two such exciting presentations, and we are starting to be quite late in the afternoon. But bear with me. I have been engaged with boards for more than seven years, and I promise some new slides today. My ambition is to use history and the last few years to hopefully be able to explore the underlying trends more clearly. So we have had quite volatile periods in terms of currency, for instance. . So all the numbers I will be sharing today are based on constant exchange rates, whether it is on sales or whether we talk about EBIT margins, etc. To give a better view of the underlying performance. And again, we have been talking a lot about sales, and revenue growth remains a high priority on our side. And when I joined back in late 2018, we were really at the starting point of changing the focus of the business. We made big changes in the commercial platform in the US. We made big investments in our European sales organization, and that was really the starting block of this journey. We have, from 2020 to 2025, delivered a 44% CAGR. With the FDA authorization of Seromine in the US back in 2022, we launched on October 22nd. Sales also accelerated. And this, as you've seen earlier today, leaves a lot of market potential remaining. Well, that is looking at the total perspective. If we look at the US specifically, because again, the US remains a very high priority for us. It is a huge market opportunity. Well, in the US we have a CAGR of 55% during the same period. So with the commercial strategy and the platform that we created in 2018, we already established good growth momentum from the start, preparing for the launch of Ceribell later on and helping to accelerate that market pickup as we launched. As you can see, the incremental growth is increasing every single year. But in terms of the relative growth in percentage, it's coming down. But again, incremental growth is increasing year by year. If we continue to focus on the numbers, because again, by all means, sales of Cerament is really the focus point currently in the US. Well, how does that market penetration go? Well, this is a slide. It is a lot of information on this slide. But this is a slide to show the data for every single year in the US. What are we gaining in terms of new access? And this is based on surgeons' first-time use. How much do we gain through adoption? So, for the surgeons who were recruited the year before, how much are they extending their usage? And the world is never perfect. You also lose some business. And that is also disclosed on this slide. And what is really positive, I believe, in this slide is when you look at how access is growing year by year, as well as adoption, with adoption increasing from 6 million to 11 million to 18 million. And as we communicated when releasing Q4 last year. Q1 this year is that we are in a stage where new access and adoption are equally important. And that is why, again, we have been talking so much about the segment-based approach. Because that is also a good way to not only drive adoption, as it really helps, but also to some extent market access and some new access. So, that is really the US. But also when we talk about Europe, Europe is coming up shy when compared to the US for two reasons. First, it is a smaller part of sales, and growth in percentage is much smaller than in the US. But part of the reason for that is also that we have been making investments lately in our so-called hybrid markets, where hybrid markets are distributor markets as a revenue model, which means it is half the price. So how do we present that to someone in a way? We need to overcome that to make the numbers comparable. I decided to look at Euro sales in units because that changed the perspective somewhat. Euro sales in total for this period, despite quite a lot of headwinds in 2025, show a CAGR of 17% in total, an increase in sales of 2.2 times since 2020. Direct markets, which consists of the UK, Germany, Sweden, Denmark, and the Netherlands, faced significant headwinds in the UK. Germany during 2025 showed a 30% CAGR, but it is also very important to look at the hybrid markets where we have done a lot of investments during the last few years, starting with Italy and Spain and extending during last year into countries and markets such as Australia, South Africa, Canada, Norway, Austria, etc. We see sales accelerating and showing a CAGR of 38%. Turning to the OpEx side of things. As has been said, we are constantly making commercial investments. This is a slide showing selling expenses, not including commissions and fees, because they are so directly related to the revenue. This is all the rest, meaning this includes personnel, marketing spend, etc. And we can see that we continue to invest commercially because we believe that is the right way also to support continued growth. We have been adding substantial headcount, especially in the last few years. So just from 2024 to 2025, we expanded our sales and marketing functions by close to 20 people, both in the US. But here also in what we call the euro booster, where we extended ambitions in our hybrid markets. And what to keep in mind is that if we just take the ten additional heads in Europe, we communicated when doing that investment that it takes 18 months until these people are returning their cost in revenue, and it takes at least five years until they reach their peak sales. So these are investments ahead of some of the revenue impact that is coming. So, what else? Well, we are not only investing commercially, we are also investing in research and development. Our R&D expenses have been accelerating during the last two years, and the main reason for that is that we are investing for the future. So if you look at this slide, you see in 2024 and 2025, colored with dotted lines, the amounts that we have spent that are much more forward-looking. These are the investments we have made in terms of our submission to the FDA in the US. These are our investments for entering the spine market, new market entries, clinical studies to get into new applications, and product development. And we will continue to invest in that pipeline because we also believe that this is a contribution to our future sales growth. And we have been hearing a lot today about all the initiatives we are undertaking in terms of our segment-driven strategies and our ambition in spine and revision arthroplasty. And despite all of those investments, with the strong sales growth that we are reporting, these costs are down to somewhere around 7% and 8% of revenue. So all in all, we have seen, when we step out of all the impact of currency and currency volatility, a very solid trajectory when we talk about operating results. It is a very solid trajectory when we talk about operating results, in this case, looking at operating results excluding the impact from long-term incentive programs and the operational operating leverage, which is marked as the grey boxes on this slide. So we can see that the operating leverage remains extremely solid and stable. And we see a clear trajectory in terms of yearly improved operating results and operating margins. And as mentioned a few times. So we not only sit on a very scalable business model, we extended production without impacting the P&L. We can see the strong operating leverage resulting from the sales growth. We deliver a lot of profit improvements, the investment level is low, all R&D expenses are expensed, and so on. And with efficient treatment of working capital. Despite the fact that we hold extensive safety inventories to ensure flexibility to the market. So we have a very solid cash conversion. So the cash conversion has tracked steadily over time, around 70% of the adjusted operating profit. And this gives us headroom. This gives us flexibility, whether it is investing in those clinical studies, investing in the R&D pipeline, investing commercially, or using part of that cash for share buybacks as an optional way to create shareholder value. So if I sum that up, I believe that just by those limited numbers of shares, we can show that we have delivered a lot of operational performance in the last few years, while still having material untapped market potential out there. As we have seen in other presentations, our market share is low in all of our main segments, highlighting the significant market potential that remains in those areas. I think that we have proven over the last few years that we have a very scalable business model, not only in terms of operating leverage, but also in terms of the lean balance sheet that we are operating with. And again, not to forget that we have a queue of interesting triggers in the short to mid-term. The Solorio study that we have been waiting for since fall 2024. And we heard from several speakers that we believe that this is, for the longer term, something that will bring value to our contacts with surgeons and hospitals in the market. Our Saturn V submission. As is always the case with the FDA, it is hard to say when, but we have a strong belief that with the experience we have in Europe using segment V, we will get there and we will be able to. To launch segment V in the US. Geographic Expansion. So we invested in hybrid markets during the last few years. We made inroads in India earlier this year. We are working with the authorities in Japan to open up that market. And we will continue to open up new markets outside the US. And again, also as we shared today, our plans are to get Segment G or V, the antibiotic-eluting properties, into Spain in the mid- to long-term. So with that, I'll leave it to you to round off the meeting.
Thank you. You can feel free to stay on the stage. We are going to do Q&A later. I promise. Last slide for the day. Concluding remarks. I said earlier what I thought you should bring home as a take-home message. The way that I would summarize the day is our strategy is proven. We're moving into the next evolution that relates to becoming more segment-specific, because customers in the different segments have different needs. We have to cater to that. We have upwardly adjusted our US market opportunity, again, underlining the growth potential that we see with Cerament in the US. We continue to invest in evidence. That is one of the core pillars of our strategy, with special emphasis on arthroplasty. That study is estimated to cost around 40 million SEK. We believe that we have a role to play in spine with an antibiotic-eluting product for the long term. We are not on-label there yet, but we are investing in that space. That study is estimated to cost around 80 million Swedish kronor, and we aim to have a regulatory submission no later than 2031. And the most important thing, however, is that we have run the numbers. You looked at the updated numbers. We looked at the upgraded numbers. You looked at the market potential. You looked at the pools of conditions where there is an inevitability of patients in this space. And you looked at the unmet need. We are very early in our growth journey. We're just getting started. So even though it's fantastic numbers that you guys have delivered, I'm absolutely convinced that the best days of BoneSupport are ahead of us and not behind us. So with that, I thank you all for taking the time to be here and am happy to take any final questions.
Thank you very much. So, do we have any final questions to wrap this up? Yes. In front here.
Thank you very much. It was on the adoption versus new access chart. That was really helpful. I wanted to see your thoughts on how that would look in the future. Could you see maybe adoption sort of start to scale ahead, and then, to follow up on that, if you could focus on the ASC channel dynamics and how you are growing there versus other settings, that would be really helpful.
Okay. So, the way that we split these questions is that I take the easy ones and Hawken takes the difficult ones. So, Hawken, can you take the first one, and I will talk about ASCs.
Now again, I think that's what we believe when we look forward, is that new access and adoption will continue to be somewhat equally important. I think it's also important to say that some of what we stated here is lost sales. Well, in that number, you find surgeons retiring from that specific practice. You find surgeons that are moving from a hospital where we had listings to hospitals where we don't have listings, which in the longer term is not necessarily negative. So I think that when looking at that slide, it is a first indication of how this looks. I think that's because we are still so early on that commercial journey with Herma G. We need more time until we can see some of the firm underlying trends. But I think that keeping 85% of the business that we had with us into the new year is a good level. Also, if we look at comparables in the US, that is good.
And on an ASC, I think it's a very relevant question, especially if you look at a medium to long term. We are a very small player in orthopedics. Honestly, we are insignificant compared to the major players. The big guys invest a lot in ASCs for the right reasons. There is a lot of patient volume moving in that direction. That is not going to go away. We see that. But where we are in our journey now, our focus is on inpatient. But Doctor Matuszewski made a really good point on that. It is going to move, and we will, of course, be part of that move. But now we like to keep things simple. Straightforward inpatient is more than we can handle at this point. But we stay very close to the trends. And because in a couple of years, it is highly likely that it will look slightly different.
Perfect. Thank you. And then just a clarification on the sales force. So the ROI that you projected, is that based on historical data you have got, or is that based on what you expect in the future?
I will say both. So that is the learning we have done with the investments that I have done over the years. And it's quite steadily around that. It takes 18 months to somewhat recover the cost in terms of revenue. And I think that what we saw in hybrid markets very much corresponds to that.
Of the U.S. And global.
That is Europe, because that is really where we have a direct sales force. So in the U.S. , we don't have the same front-end costs.
I don't know if this is a good or bad last question. Probably not. But I want to back things up a bit to just, now you have showed us your plan. How hard was it to prioritize this? I mean, you have had areas that you could go into where you could invest. You could have gone into Japan. Why? Why this, and how hard was it?
I would say saying no to things is the most important. task of the CEO and the CFO. We have to do it all the time. Prioritization is always very hard, especially when it comes to technology because it is so versatile. There are hundreds and hundreds of things that we could do with it, combining it with different things. There are a lot of ideas, some of them really good. Quite a few are pretty bad when it comes to inorganic activities. So there are a lot of things that pull our attention all the time. But at the same time, when we compare all of those alternatives compared with foot and ankle trauma arthroplasty, which is here and now, it is what we call easy. It always comes back to when we look at it rationally, we look at the numbers. We have to continue to focus here until we start seeing other data points that indicate that we need to look outside. Spine is actually an area where we think—we don't know for a fact, but we think—that there are a lot of data points indicating that this could be another important leg for bone support in the future. That is why we're trying to get into that segment. It is hard, but it is part of the job that we do, and especially with the P&L that we have, with the asset-light model and the balance sheet, it takes a lot to improve on what we already do today. So that is why we are being pretty cautious. We are pretty disciplined when it comes to inorganic activities and also moving into other segments. I think this is a very solid, logical, and rational plan that we have.
Great. Thank you for a good day.
Thank you very much. Thank you, guys.



















